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Summary 
 
Lipid homeostasis is an essential factor for proper function both at the level of a cell 
and of an organism. Dysregulation of this process is responsible for some of the 
major health concerns of our societies such as obesity and atherosclerosis. 
Considering the wide variety of lipids and the high dynamic of the system, it is clear 
that regulation is required to keep the appropriate balance between the different 
lipids. Although a few regulation pathways are already characterized, some others 
still wait to be discovered. In order to unravel new players involved in lipid 
regulation, a screening procedure was developed combining RNA interference in 
Hela cells and thin layer chromatography. Thereby, it is possible to monitor 
modifications of lipid composition resulting from siRNA knock-down. Furthermore, 
the potential of mass spectrometry as a lipid analysis tool in large-scale studies was 
evaluated. 
 
This method was then applied to an essential family of regulatory proteins, the 
kinases. Lipid composition of 600 kinases knock-downs was analyzed. Mostly, 
variations in triglyceride and cholesterol levels were observed, suggesting that these 
lipids are more subject to variation in the cells. Unfortunately, it appears that the 
screen suffered from a high-rate of off-targets effects, implying that most of the 
phenotypes observed can’t reliably be linked to the corresponding kinase knock-
downs. 
 
However, several interesting conclusions can still be derived from this screen. First, 
it was observed that several siRNA induce a decrease in cholesterol, which is 
coupled to accumulation of a new lipid. Several lines of evidence suggest that this 
new lipid is in fact a methylated sterol precursor such as lanosterol or 
demethyllanosterol. Previously, HMG-CoA reductase was considered as the rate-
limiting enzyme of cholesterol biosynthesis and the major regulated step of this 
process. These data show that another major regulation step occurs more 
downstream in the pathway at the level of methylated cholesterol precursors. 
 
Furthermore, MAPK9 was identified as a new regulator of triglyceride homeostasis 
at the cellular level. Upon MAPK9 knock-down, an increase in triglyceride content 
was observed both by thin layer chromatography and mass spectrometry. 
Accordingly, these cells present an increase in lipid droplets, the cellular organelles 
responsible for triglyceride storage. Sty1 was also identified as the functional 
homolog of MAPK9 in S. pombe for this process, as similar increase in triglyceride 
and lipid droplets is observed in a deletion strain for this gene. Although more 
detailed studies will be necessary to unravel the molecular mechanism of this 
process, these data suggest the evolutionary conserved implication of the MAP 
kinase pathway in the regulation of lipid storage both in humans and in yeasts. 
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 In today’s society, awareness has raised on the importance of lipids in health 
issues. People caring about a healthier diet have come to know the existence of 
specific lipids as important factors for their health, following the appearance of their 
names on packages of many dietary or even cosmetic products. On the other hand, 
most of the rising health concerns in developed countries have been linked to 
imbalance in lipid intake and regulation. Among others, we can mention obesity and 
the metabolic syndrome, diabetes or atherosclerosis, as consequences of the often 
too rich diet that has become a standard in the US, but also, increasingly, in Europe 
(Murray & Lopez 1997). Furthermore, the occurrence of these pathologic states is 
rapidly increasing in developing countries for it appears that an insufficient nutrition 
during early infancy, or even pregnancy, predisposes to these disorders at later 
stages of life (Caballero 2005). It is therefore essential to unravel the molecular basis 
of these diseases as well as the more general cellular factors that trigger lipid 
dysregulation. 
 
The first part of this introduction will therefore be dedicated to the current 
knowledge of the molecular basis of these major diseases, with a focus on the role 
of lipids in these processes. A general introduction on the different roles of lipids in 
our body and the main factors that control their regulation both at the organism and 
cellular levels will follow. 
 
 
 
 
Figure 1: Increase of overweight population in developing countries. 
Source: World Health Organization (WHO), 2000 
 8 
At the Crossroad between Lipids and Diseases 
 
Numerous diseases have been linked to dysregulation of specific or more general 
lipid-related processes. The complete overview of these diseases is beyond the 
focus of this thesis. However, the following chapters will focus on the most common 
ones, which present a major challenge for today’s public health systems. 
 
 
Obesity, Diabetes and the Metabolic Syndrome: a rising concern 
 
Obesity derives from overnutrition (Stein & Colditz 2004), resulting in excessive 
energy storage, mostly in adipose tissues, in the form of specific lipids, called 
triglycerides. Adipose tissues are formed of specialized cells, the adipocytes. These 
cells contain a high number of lipid droplets, cellular organelles specialized in lipid 
storage. They consist of a core of triglycerides (TAG) and cholesterol esters (CE) 
surrounded by a phospholipid monolayer (Tauchi-Sato et al 2002). These lipids can 
be mobilized in case of energy shortage and metabolized to serve as fuel for the 
Krebs cycle and the production of ATP. 
 
Triglycerides represent the densest form of energy storage and are therefore 
preferred for long-term storage. In the past, food availability could be limited and the 
accumulation of lipids was then used as an energetic reserve in case of food 
shortage. Nowadays, although the availability of food is not limiting anymore in 
westernized societies, the body has kept this important security system. However, 
energy expenditure doesn’t always compensate for energy intake, resulting over 
time in weight gain. Only very fine perturbation of the energy balance can result in 
large fluctuations in body weight. As an example, as little as 25 excessive calories 
per day (or an apple every three days) can give rise to a 50 kg excess weight at the 
age of 40. The transition to severe overweight, called obesity, is defined by a body 
mass index (BMI) exceeding 30 kg/m2 (Stein & Colditz 2004). 
 
In the US, more than 20% of adults are obese. Although the number is still lower in 
Europe, it is clearly rising. The caloric imbalance typical for obesity results from a 
combination of genetic and environmental factors. For example, mutations in genes 
controlling appetite, like the various adipokines and their corresponding receptors, 
are known to induce the disease (Tartaglia et al 1995, Zhang et al 1994). However, 
such mutations have only been found in 5% of obese individuals so far. This 
suggests that, like many pathologic conditions, obesity more likely results from 
interactions between multiple mutated genes, as well as from independent factors, 
such as calorie-rich food availability, decreased physical activity, increased 
marketing, stress and aging population. The main drawback of obesity is that it 
predisposes the individuals to various health problems, such as the metabolic 
syndrome, which is characterized by the development of type 2 diabetes, high 
blood pressure, elevated cholesterol and triglycerides blood levels, as well as 
increased probability for atherosclerosis and thrombosis (Reaven 1988). 
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Increased weight gain and concomitant development of visceral fat often induces an 
inflammatory response characterized by the overproduction of tumor necrosis factor 
alpha (TNFα) (Kahn et al 2006). Concomitantly, the fatty acids released by the 
adipocytes induce accumulation of fatty acid metabolites. These conditions lead to 
phosphorylation of insulin-receptor substrate 1 (IRS1) and decreased ability to 
activate the downstream insulin signaling (Aguirre et al 2002). In healthy individuals, 
this will be compensated by increased insulin production in the pancreas. However, 
in about one third of obese people, the pancreatic β-cells fail to counteract the 
insulin resistance, resulting in increased triglyceride hydrolysis by adipocytes, 
reduced glucose uptake and storage in muscles and liver, and consequent elevated 
glucose plasma level, a condition known as type 2 diabetes (Kahn et al 2006). 
 
Conversely, insulin resistance is responsible for hyperlipidemia (Avramoglu et al 
2006). Lipoprotein lipase is activated by insulin, while ApoB lipoprotein particles 
production by hepatocytes, in particular very-low density lipoproteins (VLDL), is 
inhibited by insulin. Consequently, insulin resistance will result in elevated 
triglycerides level in the form of ApoB lipoprotein particles in the plasma. 
Furthermore, the release of fatty acids from adipocytes will be enhanced in the 
absence of insulin, thus further increasing lipid blood level. Taken together, this 
results in an intricate interconnection between diabetes, insulin resistance and 
obesity. 
 
 
Figure 2: Obesity in the United States in 2004. 
Source: Behavioral Risk Factor Surveillance System (BRFSS) 
 
Although prevention of the disease via a healthy nutrition and an active life style 
would be the best way to decrease obesity occurrence, treatment of the already 
present pathologic condition appears as a major goal of today’s health research. 
The best cure to obesity is a combination of an energy-limited diet and increased 
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exercise. However, if this efficiently results in weight loss, more than 80% of the 
individuals will regain weight after the treatment. This is most probably due to the 
already existing dysregulation of adipokines metabolism, such as resistance to 
leptin, the main regulator of long-term appetite control. Therefore, medication is 
often necessary. The most common drug prescribed is Orlistat, which decreases 
intestinal fat absorption via inhibition of the pancreatic lipase. However, better 
understanding of the molecular basis of the disease could lead to the development 
of additional drugs. In the most advanced cases, weight loss surgery can be 
performed. This includes stomach size restriction, biliopancreatic diversion or 
removal of portion of the intestine. However, these surgeries are often inducing 
complications, and do not guarantee weight loss and reversal of the metabolic 
syndrome. 
 
 
Atherosclerosis: when lipids cause inflammation 
 
Atherosclerosis is a progressive disease characterized by the thickening and 
hardening of the arterial blood vessels. The initial step of atherogenesis consists in 
accumulation of lipids, mostly in the form of low-density lipoproteins (LDL), in the 
arterial wall. The exact molecular trigger of this event is not clear. One hypothesis 
would be that genes with anti-oxidative properties contain shear-stress response 
elements in their promoter, which are activated by the pulsative laminar blood flow, 
therefore protecting against oxidative stress (Topper & Gimbrone 1999). However, at 
branch points of arteries, the disturbed blood flow doesn’t trigger the anti-oxidative 
genes as efficiently, predisposing these sites to lesion formation. Oxidation of LDL 
results then in an inflammatory response, production of various leukocytes adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1), and recruitment of 
circulating monocytes (Dansky et al 2001). The monocytes migrate through the 
endothelial monolayer that lines the arterial lumen, towards the innermost layer of 
the arterial wall, the tunica intima (Li & Glass 2002, Libby 2002). There, they 
differentiate into macrophages and express scavenger receptor proteins able to 
recognize the modified LDL and promote their internalization (Kunjathoor et al 2002). 
Upon excessive internalization, macrophages are slowly turning into foam cells (so 
called because of their foamy appearance under the microscope due to 
accumulation of cytoplasmic lipid droplets) (Libby 2002). This lesion is called the 
fatty streak. Conversely, high-density lipoproteins (HDL) can promote efflux of 
cholesterol from the foam cells, thereby decreasing the lesion (Li & Glass 2002). 
 
As the inflammation increases, vascular smooth muscle cells migrate from the 
tunica media, the next arterial layer, towards the lesion. There, they further 
proliferate and also accumulate cholesterol, becoming foam cells as well (Li & Glass 
2002). Foam cells then eventually die, generating a necrotic core and extracellular 
lipid deposits which further propagate the inflammatory process. The formation of 
the plaque and consequent thickening of the arterial wall is first compensated by 
artery enlargement, but ultimately induce a narrowing of the vessel lumen, 
decreasing blood supply to the target organs. This usually remains asymptomatic. 
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However, upon plaque rupture, platelets adhere to the lesion, leading to obstruction 
of the bloodstream, thrombosis and in the worst case, myocardial infarction (Libby 
2002). 
 
In this context, the reduction of lipid accumulation in the circulation and in 
macrophages appears as an essential process to protect against cardiovascular 
diseases, one of the major causes of death in our society. 
 
 
 
 
Figure 3: The early steps of atherosclerosis (Libby 2002). 
Oxidation of LDL promotes inflammation and differentiation of monocytes into foam cells. 
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A wide variety of Lipids – A wide variety of Functions 
 
For long, lipids have been considered mostly as inert material performing two major 
functions: a source of energy, allowing the cell to produce the ATP necessary for its 
biological functions, as well as the main structural constituent of membranes, 
protecting the inside of the cell from the external milieu as well as allowing 
compartimentalisation of the different organelles. 
 
However, more recent studies have brought to light an enormous variety of 
functions that are performed by lipids. This can, in part, explain the existence of 
hundreds or even thousands different lipid species in a cell (Fahy et al 2005). 
 
Because of this wide variety, recent efforts have brought to the generation of a 
comprehensive classification system, defining eight lipid categories (Fahy et al 
2005). However, the next chapter will focus only on the major types of lipids found 
in human cells and their main biological functions. 
 
 
The Fatty Acids and Glycerolipids 
 
Fatty acids consist in a long carbon chain, generally ending with a carboxyl group 
(Fahy et al 2005). The carbon chain can either be saturated with hydrogen atoms, or 
contain double bonds. It is then called unsaturated. The most common ones are 
palmitic acid, a saturated chain of 16 carbon atoms and oleic acid, a mono-
unsaturated chain of 18 carbon atoms. However, a vast variety of fatty acids exists 
differing by the length of the carbon chain and the number and position of 
unsaturations. Because the free form of the fatty acid is toxic, owing to its 
detergent-like properties, it is generally coupled to coenzymeA (CoA), forming the 
fatty acylCoA, a highly reactive molecule that can be easily coupled to other lipid 
moieties to form more complex lipids. Up to three fatty acids can be coupled to 
glycerol via ester linkages to form mono-, di- and triacylglycerol respectively. Again, 
the possible combination of different fatty acids to the glycerol backbone will give 
rise to a wide variety of lipid species. 
 
Figure 4: Example of a fatty acid structure: palmitic acid. 
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Triacylglycerol (TAG) is the major storage form of lipids and is mainly found in 
specific storage organelles called lipid droplets (Brown 2001). However, in case of 
energy need, the fatty acids can easily be released by hydrolysis. They are then 
transported to the peroxisomes or the mitochondria where they can serve as 
substrate for β-oxidation, a process ultimately leading to the generation of ATP. 
 
 
Figure 5: Example of a triacylglycerol structure: tripalmitoylglycerol. 
 
Diacylglycerol (DAG) is the basic building block of glycerophospholipid and is 
therefore a major intermediate of their synthesis. It can also be released during 
signaling events, where it acts as a potent second messenger, activating members 
of the protein kinase C family (Bell et al 1986). 
 
In addition, fatty acids can be used to modify protein, serving as a membrane 
anchor, a process known as palmitoylation or myristoylation, depending of the acyl 
moiety (Linder & Deschenes 2007). They also interact with transcription factors, 
thereby influencing gene expression (Kliewer et al 1997). 
 
 
The Glycerophospholipids 
 
Glycerophospholipids are the major constituents of membranes (Fahy et al 2005). 
They are formed from a glycerol backbone linked to two fatty acids. The third 
hydroxyl group is then linked to a phosphate group, forming phosphatidic acid. 
Additional molecules can in turn be linked to the phosphate moiety (Fahy et al 2005). 
They will define the phospholipid classes. The most common head group is choline, 
but other molecules like ethanolamine, serine or inositol are also common 
headgroups. 
 
These lipids will organize themselves in bilayer structures, such as the cellular 
membranes, with their hydrophobic fatty acyl chains pointing inwards, while the 
more polar headgroups localize at the interface with the aqueous environment. 
Depending on the nature of the acyl chains, the fluidity of the membrane will vary, 
more saturated fatty acids giving rise to a tighter packing and less flexibility. This 
modulation of membrane fluidity is essential to accommodate proteins or for the 
fission and fusion events that the membranes undergo. 
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In addition, the different classes of phospholipids have been associated to different 
cellular events. Phosphatidylcholine (PC) has been shown to specifically interact 
with several proteins, such as the enzyme 3-hydroxybutyrate dehydrogenase (Loeb-
Hennard & McIntyre 2000), and to be essential for their function. It is also the 
precursor of the platelet-activating factor, the first biologically active phospholipid 
identified (Bussolino & Camussi 1995). Phosphatidylethanolamine (PE) has been 
shown to act as a chaperone for the proper folding of the lactose permease in E.coli 
(Bogdanov et al 2002). Phosphatidylserine (PS) is a well-known marker in apoptosis, 
where it moves from the inner to the outer leaflet of the plasma membrane (Schlegel 
et al 1996). Phosphatidylinositol (PI) can be further phosphorylated at various 
positions on its inositol ring, and the resulting molecules serve as specific markers 
for the various membranes of the secretory pathway, helping in the recruitment of 
specific proteins at the proper location (De Matteis et al 2002). Cardiolipin (CL), a 
unique phospholipid with four fatty acid chains localizes specifically to the 
mitochondria, where it acts as an essential cofactor for several enzymes involved in 
oxidative phosphorylation, like the cytochrome C oxidase (Robinson 1993). 
 
Although this list is far from being exhaustive, it gives an idea of the pleiotropic 
functions that can be performed by phospholipids in addition to their well-known 
structural role. 
 
Figure 6: Example of a phospholipid structure: dipalmitoylphosphatidylcholine. 
 
 
The Sphingolipids 
 
Sphingolipids are a particular type of lipids that use a sphingoid base, such as 
sphingosine, as primary building block. They can be coupled to fatty acids via an 
amide bond to form ceramide, while their free hydroxyl group can be linked to 
phosphoryl or carbohydrate moieties (Fahy et al 2005). 
 
Sphingomyelin (SM), that contains a choline group like PC, is mostly found in the 
outer leaflet of the plasma membrane, where it interacts with other lipids, like 
cholesterol and saturated phospholipids, to form membrane microdomains. These 
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microdomains are generally enriched in specific proteins and have been implicated 
in various biological events such as endocytosis (Simons & Ikonen 1997). 
 
Several intermediates of sphingolipid metabolism have been involved in signaling 
pathways. For example, ceramide has been shown to induce apoptosis and cell 
death (Lakics & Vogel 1998) while sphingosine-1-phosphate promotes cell division 
and proliferation (Maceyka et al 2002). The balance between these two 
intermediates is therefore essential in the regulation of cell fate (Maceyka et al 2002). 
 
Figure 7: Example of a sphingolipid structure: palmitoylsphingomyelin. 
 
 
The Sterols 
 
Sterols are totally different in structure from the other types of lipids described 
above. They are characterized by a four rings core structure, which can be modified 
by several functional groups differentiating the individual sterols (Fahy et al 2005). 
Cholesterol is the main sterol found in human cells. In its free form, it localizes within 
membranes and modulates their fluidity. It is a major constituent of some lipid 
membrane microdomains, where it interacts with sphingolipids (Simons & Ikonen 
1997). Because of its intrinsic toxicity, cholesterol is esterified for storage or 
transport purposes. This form is mostly found in lipid droplets and lipoprotein 
particles. 
 
In addition to its structural role, cholesterol is the precursor of numerous other 
bioactive lipids like steroid hormones, oxysterols and bile acids (Fahy et al 2005). It 
can also be linked to protein, like the morphogen Hedgehog (Porter et al 1996), 
where it serves as a membrane anchor for this protein, similarly to palmitoylation. 
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Figure 8: Example of a sterol structure: cholesterol. 
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Lipid Turnover in the body 
 
Lipids in our organism are either synthesized de novo, or taken up from nutritional 
sources at the level of the intestine. Then, transport of lipids through the body is 
achieved by lipoprotein particles, which consist of a core of triglycerides and 
cholesterol esters surrounded by a lipid monolayer and stabilized by apolipoproteins 
(Olofsson & Boren 2005). 
 
In the intestine, fatty acids, triglycerides and cholesterol are loaded onto ApoB48-
containing lipoprotein particles, called chylomicrons, which are then transported to 
the liver through the intestinal lymph (Olofsson & Boren 2005). Lipids can also be 
directly produced by the liver, which releases cholesterol and triglycerides onto 
ApoB100-containing lipoprotein particles, called VLDL (Olofsson & Boren 2005). 
These particles transport triglycerides and cholesterol towards receiving tissues 
throughout the body. Upon interaction with the receiving cells, the lipoprotein lipase 
hydrolyzes their triglyceride content. The released free fatty acids can then be taken 
up by the receiving cells (Verges 2005). As a consequence, lipoprotein particles 
become smaller and cholesterol-rich. These particles are known as intermediate 
density lipoproteins (IDL). Further metabolizing of triglycerides by the hepatic lipase 
then generates LDL (Verges 2005). LDL can be either taken up by cells that require 
cholesterol, through interaction with the LDL receptors and subsequent 
internalization, or recycled to the liver. Eventually, they can also become the target 
of macrophages, inducing atherogenesis (Li & Glass 2002).  
 
The liver and the intestine also release in the blood circulation ApoA1, which is 
responsible for the reverse cholesterol transport to the liver and ultimately for 
cholesterol clearance. The ATP-binding cassette transporter ABCA1 interacts with 
ApoA1 and facilitates cholesterol efflux from the liver and other tissues. The 
cholesterol loading of ApoA1 forms the nascent HDL (Lewis & Rader 2005). Lecithin-
cholesterol acyltransferase (LCAT), which is present on the particle, then esterifies 
cholesterol, generating mature HDL particles (Lewis & Rader 2005). Several 
proteins, such as scavenger receptor B1 and ABCG1, promote further cholesterol 
loading of HDL (Ji et al 1997, Wang et al 2004). The circulating enzyme cholesteryl 
ester transfer protein (CETP) in turn triggers the exchange of cholesterol and 
triglycerides between HDL and LDL particles (Lewis & Rader 2005). Alternatively, 
HDL particles can either interact with scavenger receptor B1 on the hepatocytes, 
removing cholesterol from the particle, or be fully catabolized by the liver or the 
kidneys (Lewis & Rader 2005). 
 
In the liver, cholesterol is converted into bile acids through multiple successive 
steps generating a soluble, detergent-like molecule that can be secreted into the 
bile. Since mammalian cells are unable to degrade the steroid nucleus of 
cholesterol, this constitutes the major pathway for cholesterol clearance (Repa & 
Mangelsdorf 2000). The bile acid synthesis is controlled by the cytochrome P450 
enzyme CYP7A, which catalyzes the first and rate-limiting step of the conversion 
(Repa & Mangelsdorf 2000). The release of cholesterol and bile acids into the bile is 
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then achieved via several transporters like ABCG5 and ABCG8, as well as the 
multidrug transporter Mdr2 (Beaven & Tontonoz 2006). 
 
Fatty acids are mostly taken up by muscles and adipocytes. In the muscle cells, 
fatty acids are degraded via β-oxidation in the mitochondria, generating ATP 
necessary for their activity. In adipocytes, fatty acids are converted to TAG and 
stored in lipid droplets, from which they get released in case of energy shortage. 
Upon fatty acid uptake, adipocytes also release leptin, a hormone that signals to the 
hypothalamus and thereby induces satiety (Campfield et al 1995, Pelleymounter et 
al 1995). In addition, leptin inhibits lipid biosynthesis and excessive lipid uptake by 
non-adipose tissues to protect them from the deleterious effects of elevated lipid 
levels (Unger 2003). The lipotoxicity of fatty acids in these cells seem to be mainly 
the result of their degradation via non-oxidative pathways, inducing, among other 
effects, the production of ceramide, a secondary messenger able to induce 
apoptosis (Unger & Orci 2002). 
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Cellular Regulation of Lipids 
 
As it has been mentioned above, cells contain a wide variety of lipid species, the 
individual nature of each being essential for various cellular functions. These lipids 
can either be obtained from external sources and be distributed throughout the 
body by lipoproteins, or they can be synthesized de novo by the cells. Although 
most of the de novo lipid synthesis occurs in the liver, each cell possesses the 
active machinery to synthesize lipids. The lipid pool of a cell is therefore very 
dynamic. To keep a proper balance between the individual lipids in a cell, regulation 
of this complex system appears essential. Several regulation processes are already 
partially characterized and the next chapter will focus on the current knowledge on 
the most relevant ones. 
 
 
A Cholesterol Sensor: The SREBP pathway 
 
In 1993, Briggs and colleagues identified a transcription factor, a basic helix-loop-
helix leucine zipper, able to activate gene transcription in a cholesterol dependent 
manner by interacting with sterol regulatory element (SRE) found in the promoter of 
its target genes (Briggs et al 1993, Wang et al 1993). Since then, tremendous efforts 
have been made to understand the mechanism governing the action of these SRE 
binding proteins (SREBP). Two different SREBP genes are present in mammalian 
cells, encoding for three different isoforms. As SREBP-2 mostly regulates genes 
involved in cholesterol biosynthesis and uptake, SREBP1a and 1c are more involved 
in the regulation of fatty acid synthesis (Rawson 2003). However, the product of 
these genes is much longer than the nuclear form that was initially discovered. They 
encode for a precursor protein containing two transmembrane domains that 
localizes in the endoplasmic reticulum (ER). SREBP interacts there with another 
membrane protein, SREBP-cleavage-activating protein (SCAP) (Hua et al 1996). 
SCAP is necessary for the transport of SREBP to the Golgi apparatus, where 
SREBP can be further processed (Nohturfft et al 2000). SCAP contains eight 
membrane-spanning helices, five of which form the sterol-sensing domain. Upon 
interaction with cholesterol, SCAP modifies its conformation (Brown et al 2002) and 
interacts with insulin induced genes (Insig) proteins, which retain the SCAP-SREBP 
complex in the ER (Yang et al 2002b). However, when the cholesterol level 
decreases, this interaction is impaired and the complex can partition in COPII 
vesicles and travel to the Golgi (Espenshade et al 2002). There, SREBP is 
successively cleaved by Site-1 protease (S1P) in its luminal loop (Duncan et al 1997) 
and by Site-2 protease (S2P) in its N-terminal transmembrane helices (Rawson et al 
1997), releasing a transcription factor fragment that is transported to the nucleus by 
importin β (Lee et al 2003a) to induce target genes expression. 
 
In addition to its action as a retention factor, Insig also acts at another level of 
cholesterol regulation. HMG-CoA reductase is the enzyme responsible for the 
formation of mevalonate, the rate-limiting step of sterol biosynthesis (Goldstein & 
Brown 1990). It is transcriptionally regulated by SREBP. But in addition, it contains, 
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like SCAP, a sterol-sensing domain driving its interaction with Insig upon binding 
with sterols, in particular with the cholesterol precursor lanosterol (Sever et al 2003, 
Song et al 2005a). Insig favors its ubiquitylation and subsequent proteolytic 
degradation (Song et al 2005b). Insig is thereby involved at two different levels in 
down-regulation of sterol biosynthesis, although the molecular mechanisms seem 
very different in both cases. 
 
Interestingly, SREBP homologues have been found in all the metazoan genomes 
sequenced so far, even in the species auxotroph for cholesterol (Rawson 2003). For 
example, in Drosophila, the SREBP-SCAP system has been shown to respond to 
the level of PE, rather than cholesterol (Dobrosotskaya et al 2002), and to regulate 
several genes implicated in fatty acids and phospholipids biosynthesis, suggesting a 
broader spectrum of possible regulation by this system. 
 
 
Figure 9: Two-steps processing of SREBP (Rawson 2003). 
 
 
The Nuclear Hormone Receptors LXRs and PPARs 
 
Nuclear hormone receptors are transcription factors that are activated upon binding 
of small lipophilic ligands (Whitfield et al 1999). Several members of this protein 
family have been shown to regulate lipid metabolism, in particular the liver X 
receptors (LXR) and the peroxisome proliferator-activated receptors (PPAR). 
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Most of the members of this family were initially cloned on the basis of sequence 
homology with the steroid hormone receptors. They were referred to as orphan 
receptors, because of the absence of any known physiological ligand. But in 1997, 
Lehmann et al. identified oxysterols as potent regulators of LXR (Lehmann et al 
1997). Oxysterols are oxygenated sterols that are formed as by-products of 
cholesterol, bile acids or steroid hormones biosynthesis (Olkkonen & Levine 2004). 
They are therefore good markers for cholesterol accumulation. Upon interaction with 
LXR, they induce recruitment of coactivators and expression of several genes 
implicated in reverse cholesterol transport and cholesterol clearance (Kalaany & 
Mangelsdorf 2006, Zelcer & Tontonoz 2006). There are two LXR genes. While LXRβ 
is ubiquitously expressed, LXRα is mostly found in the liver (Repa & Mangelsdorf 
2000). However, they have very similar structure and activities (Zelcer & Tontonoz 
2006). 
 
Among the genes that are up-regulated by LXR, one can find ABCA1 (Repa et al 
2000b) and ABCG1 (Venkateswaran et al 2000), two ABC transporters facilitating 
cholesterol loading on HDL, and thereby clearance of cholesterol from peripheral 
tissues. In particular, their action on cholesterol clearance from macrophages gives 
LXR a protective role against atherosclerosis. This is further promoted by up-
regulation of various genes implicated in lipoprotein remodeling (Kalaany & 
Mangelsdorf 2006, Zelcer & Tontonoz 2006). But the anti-atherogenic action of LXR 
is probably not limited to the regulation of cholesterol metabolism, since they have 
also been shown to down-regulate several inflammatory genes, probably by 
competition with other transcription factors for coactivators or via down-regulation 
of the NFκB pathway (Zelcer & Tontonoz 2006). However, LXR also activates 
SREBP1c, thereby inducing lipogenesis (Repa et al 2000a). This may be a way to 
protect from cholesterol overload by allowing cholesterol esterification and storage 
(Goldstein et al 2006). 
 
LXR also activates ABCG5 and ABCG8 (Repa et al 2002). These two proteins form a 
heterodimer that limits the absorption of cholesterol and phytosterols in the gut, 
probably by pumping them out of the cells (Lee et al 2001). They also promote 
cholesterol efflux from hepatocytes into the bile (Yu et al 2002). Similarly, CYP7A, 
the rate-limiting enzyme of bile acid synthesis, is also a target of LXR in mice, 
however not in humans (Chiang et al 2001, Peet et al 1998). 
 
The other important nuclear hormone receptors implicated in lipid metabolism are 
PPARs. Three isoforms exist: PPARα, PPARγ and PPARδ (Li & Glass 2004). They are 
activated by a wide variety of fatty acids, with overlapping specificity between the 
isoforms (Berger & Moller 2002). Contrary to the analogous functions of the two LXR 
isoforms, the different PPARs are implicated in different metabolic processes. For 
example, PPARα up-regulates fatty acid oxidation through the transcriptional 
activation of several enzymes of this pathway (Chawla et al 2001b). It also up-
regulates ABCD2 and ABCD3, two ABC transporters implicated in the transport of 
fatty acids to peroxisomes (Fourcade et al 2001). The general outcome of PPARα 
activation is therefore a decrease in triglyceride level. On the contrary, PPARγ 
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promotes fat storage through up-regulation of adipocyte differentiation factors, 
lipogenic enzymes and genes involved in fatty acid uptake (Beaven & Tontonoz 
2006, Chawla et al 2001b). Activation of PPARγ is also critical for glucose 
homeostasis (Li & Glass 2004), in particular through the up-regulation of the insulin-
dependent glucose transporter GLUT4 (Wu et al 1998). In addition, an interesting 
crosstalk is observed with the LXR pathway, since PPARγ, as well as PPARα, 
induce LXRα, thereby activating lipogenesis and the reverse cholesterol pathway 
(Chawla et al 2001a, Chinetti et al 2001). The role of PPARδ is less well understood, 
but it seems to be mostly implicated in the regulation of fatty acid oxidation (Wang 
et al 2003). It has also been shown to regulate the production of myelin, an 
insulating phospholipid layer surrounding the axons of some neurons (Berger & 
Moller 2002). 
 
 
A New Class of Metabolic Regulators: The microRNAs 
 
MicroRNAs (miRNA), a new class of regulatory molecules, have been implicated in 
the regulation of lipid metabolism. MiRNAs are short non-coding RNA molecules 
that can bind to partially complementary mRNA, inducing their translational 
repression and eventually their degradation, ultimately leading to depletion of the 
target protein (Bartel 2004, Kim & Nam 2006). More than 300 miRNAs sequences 
have been identified so far in the human genome (Kim & Nam 2006, Krutzfeldt & 
Stoffel 2006). The function of most of them is still unknown, but several have been 
implicated in the regulation of development, differentiation and metabolism 
(Krutzfeldt & Stoffel 2006). The first study implicating miRNAs in lipid metabolism 
was carried out in Drosophila (Xu et al 2003). Overexpression of drosophila miR-14 
induces a decrease in triglyceride level. However, the mechanism of this down-
regulation was not determined. Conversely, depletion of drosophila miR-278 also 
induces a decrease in triglyceride level, suggesting an important role for miRNAs in 
the regulation of triglyceride metabolism (Teleman et al 2006). Although no homolog 
of these miRNAs has been found in mammals, other miRNAs have been implicated 
in the regulation of adipocyte differentiation (miR-143 (Esau et al 2004)) and 
cholesterol homeostasis. Two studies (Esau et al 2006, Krutzfeldt et al 2005) have 
shown that depletion of miR-122 induces a decrease in plasma cholesterol level in 
mice (figure 10, right), probably owing to an observed decrease in the expression of 
cholesterol biosynthetic genes such as HMG-CoA reductase and mevalonate 
kinase. However, the mechanism by which miRNAs could activate gene expression 
is currently unknown. In addition, Esau et al. showed a comparable modulation of 
triglyceride level, and down-regulation of the fatty acid synthase and other lipogenic 
genes in miR-122 depleted hepatocytes (Esau et al 2006). 
Since the function of most miRNAs is still unknown, it is likely that more will be 
implicated in the regulation of lipid metabolism. Systematic identification of miRNAs 
expressed in liver and adipocytes have been carried out recently (Esau et al 2004, 
Fu et al 2005, Kajimoto et al 2006), suggesting new potential candidates for such 
regulators. 
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Figure 10: Decrease in fatty acid synthesis and cholesterol levels upon miR-122 depletion 
(denoted by ASO) (Esau et al 2006). 
 24 
 
 
 
 
 
 
Aim 
 25 
Aim of the thesis 
 
The cell is a very dynamic system, continuously exchanging information and 
molecules with its surrounding, and among them, lipids. As it has been pointed out 
in the introduction, the importance of lipids goes far beyond their structural role in 
membranes. It is therefore essential to keep a proper balance between the wide 
variety of lipid entities present in the cells. To achieve this, cells developed tight 
regulation systems. 
 
Although some regulation processes have been already uncovered and are 
beginning to be understood, these would be insufficient to fully regulate such a 
complex cellular lipid homeostasis. It is therefore highly expected that other 
regulation systems still need to be unraveled. This is precisely the aim of this thesis. 
 
Therefore, the first goal of this thesis is the design of a screening procedure that 
allows identification of such regulators. Systematic knock-down of individual genes 
can be achieved using a recently discovered cellular process, RNA interference. 
Combining this technique with lipid analysis methods appears as a good way to 
monitor variation of lipid composition upon gene knock-downs. 
 
Then, this procedure can be applied to the study of gene families that potentially 
play a role in lipid regulation. In particular, kinases appear as good candidates for 
such regulators, considering their wide implication in the regulation of other 
biological processes. 
 
Finally, the results of the screen are analyzed, and the most promising candidates 
further characterized, leading to the potential identification of new regulators of lipid 
homeostasis. 
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Material and Methods: Human cells 
 
 
Material 
 
Dulbecco’s modified Eagle’s medium with high glucose and sodium pyruvate 
(DMEM), Opti-MEM, Fetal Bovine Serum (FBS) and trypsin were obtained from 
Gibco (Karlsruhe, Germany). Delipidated FBS was prepared as described previously 
(Thiele et al 2000). Briefly, lipids were extracted from FBS using successively a 
diisopropylether/butanol 2:1 mix and pure diisopropylether. Then, the upper phase 
was dialyzed against phosphate buffered saline (PBS). After several dialysis steps, 
delipidated FBS was filter-sterilized and kept frozen until use. 
 
Lipid standards were from Sigma (St. Louis, MO), except phosphatidylserine (PS), 
sphingomyelin (SM), phosphatidylinositol (PI) and glucosylceramide which were 
from Avanti (Alabaster, AL), cholesterol ester from AppliChem (Darmstadt, 
Germany), oleate from Acros (Geel, Belgium), ceramide from Matreya biochemicals 
(Pleasant Gap, PA), lophenol from ResearchPlus (Manasquan, NJ), desmosterol and 
epoxycholesterol from Steraloids (Newport, RI). 14C-acetate was obtained from 
Amersham (Freiburg, Germany) and 3H-oleate from Hartmann Analytic 
(Braunschweig, Germany). 
 
The siRNA kinase library was obtained from Ambion (Austin, TX). Other siRNAs were 
also from Ambion, unless mentioned otherwise and are described in table 1. 
EsiRNAs were a kind gift from Dr. R. Kittler (Kittler et al 2004). 
 
Real-Time PCR primers were from Biospring (Frankfurt, Germany). Sequences can 
be found in table 2. Rabbit polyclonal antibody against IKK1 was from Santa Cruz 
(Heidelberg, Germany). Rabbit polyclonal antibody against JNK2 and mouse 
monoclonal antibody against phospho-JNK were from Cell Signaling Technologies 
(Danvers, MA). Rabbit polyclonal antibodies against ATGL and HSL were from 
Cayman chemical (Ann Harbor, MI). Horseradish peroxidase (HRP)-conjugated 
donkey anti-mouse and donkey anti-rabbit immunoglobulin G (IgG) secondary 
antibodies were from Jacksons Immunological (West Grove, PA).  
 
 
Cell culture 
 
Hela cells and A431 cells were cultured in DMEM supplemented with 10% FBS. 
Cells were passaged regularly using trypsin to maintain them in exponential growth 
phase and were tested for the absence of mycoplasma on a regular basis 
(Stratagene, Amsterdam, The Netherlands). 
 28 
Table 1: List of siRNAs used in this work (except the kinase library). 
 
Gene ID number Company RefSeq Number
Other names used in the thesis 
or sequences
ALS2CR2 1171 Ambion NM_018571 siRNA1 (screen), O1
ALS2CR2 1266 Ambion NM_018571 siRNA2 (screen), O2
ALS2CR2 1361 Ambion NM_018571 siRNA3 (screen), O3
ATR 82 Ambion NM_001184 siRNA1 (screen), O1
ATR 103302 Ambion NM_001184 siRNA2 (screen), O2
CASK 446 Ambion NM_003688 siRNA1 (screen), O1
CASK 447 Ambion NM_003688 siRNA2 (screen), O2
CASK 448 Ambion NM_003688 siRNA3 (screen), O3
CASK 139314 Ambion NM_003688 siRNA1 (new), N1
CASK 139315 Ambion NM_003688 siRNA2 (new), N2
CASK 139316 Ambion NM_003688 siRNA3 (new), N3
CASK 109507D02 Invitrogen NM_003688
CASK 109507D04 Invitrogen NM_003688
CASK 109507D05 Invitrogen NM_003688
CASK SI02223368 Qiagen NM_003688
CASK SI02223375 Qiagen NM_003688
CKMT2 175 Ambion NM_001825 siRNA1 (screen), O1
CKMT2 176 Ambion NM_001825 siRNA2 (screen), O2
CKMT2 177 Ambion NM_001825 siRNA3 (screen), O3
CSF1R 641 Ambion NM_005211 siRNA1 (screen), O1
CSF1R 642 Ambion NM_005211 siRNA2 (screen), O2
CSF1R 643 Ambion NM_005211 siRNA3 (screen), O3
CSF1R 146601 Ambion NM_005211 siRNA1 (new), N1
CSF1R 146602 Ambion NM_005211 siRNA2 (new), N2
CSF1R 146603 Ambion NM_005211 siRNA3 (new), N3
CSNK1G2 115 Ambion NM_001319 siRNA1 (screen), O1
CSNK1G2 116 Ambion NM_001319 siRNA2 (screen), O2
CSNK1G2 117 Ambion NM_001319 siRNA3 (screen), O3
EG5 custom Ambion NM_004523
CUGAAGACCUGAAGACAAUtt 
AUUGUCUUCAGGUCUUCAGtt
EPHB3 529 Ambion NM_004443 siRNA1 (screen), O1
EPHB3 530 Ambion NM_004443 siRNA2 (screen), O2
EPHB3 531 Ambion NM_004443 siRNA3 (screen), O3
FLT1 190 Ambion NM_002019 siRNA1 (screen), O1
FLT1 191 Ambion NM_002019 siRNA2 (screen), O2
FLT1 192 Ambion NM_002019 siRNA3 (screen), O3
IKK1 (CHUK) 112 Ambion NM_001278 siRNA1 (screen), O1
IKK1 (CHUK) 113 Ambion NM_001278 siRNA2 (screen), O2
IKK1 (CHUK) 114 Ambion NM_001278 siRNA3 (screen), O3
IKK1 (CHUK) 145720 Ambion NM_001278 siRNA1 (new), N1
IKK1 (CHUK) 145721 Ambion NM_001278 siRNA2 (new), N2
IKK1 (CHUK) 145722 Ambion NM_001278 siRNA3 (new), N3
LAK 1075 Ambion NM_025144 siRNA1 (screen), O1
LAK 1076 Ambion NM_025144 siRNA2 (screen), O2
LAK 103610 Ambion NM_025144 siRNA3 (screen), O3
LCK 668 Ambion NM_005356 siRNA1 (screen), O1
LCK 669 Ambion NM_005356 siRNA2 (screen), O2
LCK 670 Ambion NM_005356 siRNA3 (screen), O3
LCK 143990 Ambion NM_005356 siRNA1 (new), N1
LCK 143991 Ambion NM_005356 siRNA2 (new), N2
LCK 143992 Ambion NM_005356 siRNA3 (new), N3
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Gene ID number Company RefSeq Number
Other names used in the thesis 
or sequences
LCK SI00075992 Qiagen NM_005356
LCK SI00075999 Qiagen NM_005356
LCK SI00076006 Qiagen NM_005356
MAP3K4 1470 Ambion
NM_005922 
NM_006724
siRNA1 (screen), O1
MAP3K4 1564 Ambion
NM_005922 
NM_006724
siRNA2 (screen), O2
MAP3K4 1654 Ambion
NM_005922 
NM_006724
siRNA3 (screen), O3
MAP3K4 144116 Ambion
NM_005922 
NM_006724
siRNA1 (new), N1
MAP3K4 144117 Ambion
NM_005922 
NM_006724
siRNA2 (new), N2
MAP3K4 144118 Ambion
NM_005922 
NM_006724
siRNA3 (new), N3
MAPK9 1452 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA1 (screen), O1
MAPK9 1547 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA2 (screen), O2
MAPK9 1637 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA3 (screen), O3
MAPK9 142316 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA1 (new), N1
MAPK9 142317 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA2 (new), N2
MAPK9 142318 Ambion
NM_139070 
NM_139069 
NM_002752 
NM_139068
siRNA3 (new), N3
MAPK9 SI00300797 Qiagen
NM_139070 
NM_139069 
NM_002752 
NM_139068
MAPK9 SI02222913 Qiagen
NM_139070 
NM_139069 
NM_002752 
NM_139068
NFKB1 5213 Ambion NM_003998
NFKB2 115299 Ambion NM_002502
NFKB2 143618 Ambion NM_002502
NFKB2 143619 Ambion NM_002502
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Gene ID number Company RefSeq Number
Other names used in the thesis 
or sequences
PDXK 440 Ambion NM_003681 siRNA1 (screen), O1
PDXK 441 Ambion NM_003681 siRNA2 (screen), O2
PDXK 442 Ambion NM_003681 siRNA3 (screen), O3
PDXK 139305 Ambion NM_003681 siRNA1 (new), N1
PDXK 139306 Ambion NM_003681 siRNA2 (new), N2
PDXK 139307 Ambion NM_003681 siRNA3 (new), N3
PDXK 109507E01 Invitrogen NM_003681
PDXK 109507E04 Invitrogen NM_003681
PDXK 109507E05 Invitrogen NM_003681
PDXK SI00054593 Qiagen NM_003681
PDXK SI00054600 Qiagen NM_003681
PDXK SI00288071 Qiagen NM_003681
PHKG2 50 Ambion NM_000294 siRNA1 (screen), O1
PHKG2 51 Ambion NM_000294 siRNA2 (screen), O2
PHKG2 52 Ambion NM_000294 siRNA3 (screen), O3
PHKG2 110737 Ambion NM_000294 siRNA1 (new), N1
PHKG2 118254 Ambion NM_000294 siRNA2 (new), N2
PHKG2 118293 Ambion NM_000294 siRNA3 (new), N3
PRKCL1 312 Ambion
NM_213560 
NM_002741
siRNA1 (screen), O1
PRKCL1 313 Ambion
NM_213560 
NM_002741 siRNA2 (screen), O2
PRKCL1 314 Ambion
NM_213560 
NM_002741
siRNA3 (screen), O3
PRKWNK1 1174 Ambion NM_018979 siRNA1 (screen), O1
PRKWNK1 1269 Ambion NM_018979 siRNA2 (screen), O2
PRKWNK1 1364 Ambion NM_018979 siRNA3 (screen), O3
RIPK4 1177 Ambion NM_020639 siRNA1 (screen), O1
RIPK4 1272 Ambion NM_020639 siRNA2 (screen), O2
RIPK4 1367 Ambion NM_020639 siRNA3 (screen), O3
RIPK4 113612 Ambion NM_020639 siRNA1 (new), N1
RIPK4 113613 Ambion NM_020639 siRNA2 (new), N2
RIPK4 133160 Ambion NM_020639 siRNA3 (new), N3
ROCK2 595 Ambion NM_004850 siRNA1 (screen), O1
ROCK2 596 Ambion NM_004850 siRNA2 (screen), O2
ROCK2 597 Ambion NM_004850 siRNA3 (screen), O3
ROCK2 137769 Ambion NM_004850 siRNA1 (new), N1
ROCK2 137770 Ambion NM_004850 siRNA2 (new), N2
ROCK2 137771 Ambion NM_004850 siRNA3 (new), N3
ROCK2 109507E07 Invitrogen NM_004850
ROCK2 109507E10 Invitrogen NM_004850
ROCK2 109507E11 Invitrogen NM_004850
ROCK2 SI02223746 Qiagen NM_004850
ROCK2 SI02223753 Qiagen NM_004850
SOAT1 4490 Ambion NM_003101 siRNA1
SOAT1 4586 Ambion NM_003101 siRNA2
SOAT1 4679 Ambion NM_003101 siRNA3
TRIO 848 Ambion NM_007118 siRNA1 (screen), O1
TRIO 849 Ambion NM_007118 siRNA2 (screen), O2
TRIO 103343 Ambion NM_007118 siRNA3 (screen), O3
TRIO 103427 Ambion NM_007118 siRNA1 (new), N1
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Table 2: List of RT-PCR primers used in this work. 
 
 
 
siRNA transfection 
 
4000 Hela cells were plated in 80µl growth medium in each well of a 96 well-plate 
20h before transfection.  Oligofectamine (Invitrogen, Karlsruhe, Germany) was mixed 
with Opti-MEM medium in a 1:6.5 ratio and incubated for 5’. For each well, 10pmole 
siRNA were mixed with 17µl Opti-MEM medium and 3µl of the oligofectamine mix 
prepared above. The siRNA mix was incubated for 20’ to allow formation of the 
cationic liposome/RNA complex and then added to the cells. For the screen, the 
transfection procedure was automated and performed on a Tecan Freedom Evo 
workstation (Tecan, Mannedorf, Switzerland) under sterile conditions. 100µl fresh 
growth medium was added to the cells 4h after transfection (except for the screen). 
Except indicated otherwise, growth medium was exchanged 48h after transfection 
for 100µl DMEM medium supplemented with 10% delipidated FBS. For lipid 
analysis by Thin Layer Chromatography (TLC), 2µCi of 14C-acetate were added in 
each well 56h after transfection. Lipid extracts or cells were harvested 72h after 
transfection. 
 
 
esiRNA transfection 
 
2000 Hela cells were plated in 100µl growth medium in each well of a 96 well-plate 
20h before transfection.  Oligofectamine was mixed with serum-free DMEM medium 
in a 1:6 ratio and incubated for 5’. For each well, 25ng esiRNA were mixed with 7µl 
Opti-MEM medium and 3µl of the oligofectamine mix prepared above. The esiRNA 
mix was incubated for 20’ to allow formation of the cationic liposome/RNA complex 
and then added to the cells. 100µl fresh growth medium was added to the cells 4h 
gene forward primer reverse primer
SOAT1 CACGTTCCTGGACTTGTCGTTAC TCAGGGAGCTACCCAATCTTCA
GAPDH-1 TCGACAGTCAGCCGCATCT CCCCATGGTGTCTGAGCG
GAPDH-2 CAAGGTCATCCATGACAACTTTG GGCCATCCACAGTCTTCTGG
tubulin ACTGGCATCCTGCTTTCCAGT GGCTCTGTAGCTCCCCATGTACT
IKK1 CAAGATGGGGAGACTTCAGC ATTGCCCTGTTCCTCATTTG
ATR CACCACCAGACAGCCTACAA AACATCACCCTTGGACCAGA
TRIO AAGCAGCAGCAGTAGCAACA TTTGAACGACCTCTCCTTGG
RIPK4 AGGATGAGGACCAGTGGACA GAGGCGTTCTTCTCCAACAG
PRKWNK1 AACCAGCAGCACAAACACTG ATCTGTGAATGTGCCCTTCC
ROCK2 TAAGGAAAACCCAGGCAGAA TAACTTGGCAGTCTCCAGCA
CASK GAGATTCCCCTTCCACTTCC TCGTCCTTTTGGTTGGGTAG
MAPK9 CTGCGTCACCCATACATCAC CTTTCTTCCAACTGGGCATC
PDXK CGTGTGTGATCCAGTCTTGG CGGCACCACTTTTTCTTTGT
MAP3K4 CAGGAGCAGACATCCAGTCA TGGCATTGCTTATCCTGTTG
AGPAT GCATCATCGGCTGGTTCGTG TGCTCTGGTGGTTGGAGACG
LIPIN1 GCAGAAGAACCCAGAAATGC TCAATGGGCTGGACTCTTTC
ATGL CGGGTCACCAACACCAGCATC ACATCTCTCGCAGCACCAGGG
HSL CAGTTCACGCCTGCCATCCG CGTTTGTAGTGCTCCCCGAAGG
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after transfection. Except indicated otherwise, growth medium was exchanged 48h 
after transfection for 100µl DMEM medium supplemented with 10% delipidated 
FBS. For lipid analysis by TLC, 2µCi of 14C-acetate were added in each well 56h 
after transfection. Lipids were extracted 72h after transfection. 
 
 
One-phase lipid extraction and TLC analysis 
 
Lipids were extracted directly from the wells using 15µl MeOH/CHCl3 5:1, unless 
indicated otherwise. Samples were applied onto the TLC plates (Merck, Darmstadt, 
Germany) using either capillaries or a multichannel pipette (Eppendorf, Hamburg, 
Germany). TLC plates were developed in a glass chamber containing 
EtOH/water/triethylamine/CHCl3 50/10/35/35 till 2/3 of the plate, dryed and then 
further developed with hexane/ethylacetate 5:1 till the top of the plate. Radioactive 
samples were visualized by exposure on a phosphoimager plate for 1 to 3 days and 
subsequent reading by the phosphoimager (Fuji, Dusseldorf, Germany). Non-
radioactive samples were revealed by charring with 20% H2SO4 aqueous solution 
and heated up to 250ºC. 
 
 
Bligh and Dyer lipid extraction 
 
Cells were scraped in 1ml PBS, supplemented with 0.5mM MgCl2 and CaCl2 and 
transferred to a tube containing 4ml MeOH/CHCl3 2:1. Samples were mixed and 
centrifuged at 4000g on a multifuge 3 S-R (Heraeus Holding, Hanau, Germany). 
Supernatant was transferred to a fresh tube, then 1ml of 20mM acetic acid and 1ml 
CHCl3 were added. Samples were mixed and centrifuged again at 4000g. The 
organic phase was transferred to a new tube and 50µl of 1M citric acid and 2ml 
CHCl3 were added to the aqueous phase. Samples were mixed and centrifuged 
again at 4000g. The organic phases were combined and evaporated under a stream 
of nitrogen. Dried lipids were dissolved in 30µl MeOH/CHCl3 1:2. 
 
 
Lipid profile comparison and quantification 
 
For analysis of the TLC plates, the radioactive signal revealed by the 
phosphoimager was initially analyzed using the Image Gauge software (Fuji, 
Dusseldorf, Germany). Individual lipid intensity profiles were recovered via this 
program and then transferred to the Graph Explorer software designed by Yannis 
Kalaidzidis. For profile comparison, lipid intensities were normalized on the level of 
PC. When necessary, alignment of the profiles was performed. For quantification, 
the different peaks were fitted using Gaussian curves. The area below the different 
curves was retrieved and transferred to Excell (Microsoft, Munich, Germany). There, 
results were normalized on the total lipid signal. In the case of the specific analysis 
of cholesterol ester levels in SOAT1 knock-down, only the peaks corresponding to 
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TAG and cholesterol ester were fitted and their ratio was normalized to the ratio of 
the non-transfected negative control. 
 
 
Clustering 
 
The different phenotypes were first converted into a numerical representation. For 
each lipid peak, a phenotype readily visible on the TLC plate was assigned a value 
of 3 while a phenotype revealed by profile comparison was assigned a value of 2. 
The numerical table was loaded into CUPID and clustered by k-means clustering 
using Pearson correlation. Annotation was performed using CUPID and corrected 
manually when needed. 
 
 
Protein quantification 
 
To test the potential of protein determination methods in the context of the 
screening assay, bovine serum albumin (BSA, AppliChem, Darmstadt, Germany) 
solutions of various concentrations (containing up to 10µg BSA) were analyzed in 
the presence or absence of 2% sodium dodecyl sulfate (SDS, Serva, Heidelberg, 
Germany). In addition, different amount of cells were plated in 96 well-plates and 
grown for 20h, lipids were extracted using MeOH/CHCl3 5:1 as described above 
before protein determination. Cells were then treated with 10µl SDS 2%. For the 
Bradford assay (Sigma, St. Louis, MO), 200µl of a 1/15 diluted Bradford solution 
was added on the BSA standard solution or on the cells and, after 10’ incubation, 
absorbance was measured at 570 nm on a Digiscan 400 microplate reader (Asys, 
Dornstadt, Germany). For the BCA assay (Perbio, Bonn, Germany), 200µl of the BCA 
mix was added to the samples and, after 30’ incubation at 37ºC, absorbance was 
measured at 550 nm. For the fluorescamine assay, 100µl sodium borate 0.1M pH 
8.9 and 20µl fluorescamine (0.25 mg/ml, Sigma, St. Louis, MO) were added to the 
samples and fluorescence was measured using a Fluoroskan Ascent CF microplate 
reader (Thermo Labsystems, Vantaa, Finland) with excitation at 380 nm and 
emission at 485 nm. 
 
 
DNA quantification 
 
After lipid extraction, 200µl of propidium iodide (3µg/ml, Sigma, St. Louis, MO) were 
added to the wells and incubated in the dark for 3h, unless indicated otherwise. 
Fluorescence emission was measured using a Fluoroskan Ascent CF microplate 
reader (Thermo Labsystems, Vantaa, Finland) with excitation at 530 nm and 
emission at 620 nm. 
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Treatment with kinase inhibitors or chemicals 
 
For inhibition of IKK, parthenolide (Biomol International, Exeter, United Kingdom) 
was added to the cells at the indicated concentrations 24h before lipid extraction. 
For lipid analysis by TLC, 2µCi of 14C-acetate were added in each well 6h later. 
 
For inhibition of JNK, SP600125 (Sigma, St. Louis, MO) was added to the cells at 
the indicated concentrations 24h before lipid extraction. For lipid analysis by TLC, 
2µCi of 14C-acetate were added in each well 6h later. 
 
For rescue of the PDXK knock-down, pyridoxal phosphate (Sigma, St. Louis, MO) 
was added to the cells 48h after transfection with a pool of three siRNA sequences 
against PDXK. Concentrations of pyridoxal phosphate were varied between 0.01 
and 100 µM. For lipid analysis by TLC, 2µCi of 14C-acetate were added in each well 
6h later. Lipids were extracted 72h after transfection. 
 
 
Oleate feeding 
 
Oleate was added to the cells 4h after transfection to a final concentration of 50µM. 
In addition, 1µCi of 3H-oleate was added in each sample. Lipids were extracted as 
described above 48h after transfection and resolved by TLC. The TLC plate was 
then dipped in LumaSafe solution (Lumac-LSC, Groningen, The Netherlands) and 
exposed on MP films (Amersham, Freiburg, Germany) for 6h at -80ºC. 
 
 
JNK activation 
 
UV activation of JNK was achieved by 10’ irradiation using a 200 W high-pressure 
Oriel Photomax mercury lamp (Newport, Irvine, CA), which filter out wavelengths 
shorter then 310 nm. Prior to irradiation, growth medium was removed from the 
cells and replaced by TBS. Cells were kept on ice during irradiation to avoid 
overheating of the samples. Then, cells were transferred back to their growth 
medium and kept at 37ºC for 20’ prior protein extraction using Laemmli buffer. 
 
Anisomycin activation of JNK was achieved by addition of anisomycin (Sigma, St. 
Louis, MO) to a final concentration of 250ng/ml directly in the growth medium. Cells 
were further grown for 2h prior protein extraction using Laemmli buffer. 
 
 
Mass spectrometry 
 
For MS analysis on the Esi-Qq-Tof mass spectrometer, cells were extracted in 30µl 
MeOH/CHCl3 5:1 supplemented with 5mM ammonium acetate. Aliquot from these 
samples were analyzed in negative ion mode on a QSTAR Pulsar/QqTOF mass 
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spectrometer (MDS Sciex, Concord, Canada). Ionization voltage was set to -0.9kV 
and gas pressure to 0.1psi. Then, the rest of the samples was dried under a stream 
of nitrogen and lipids were re-suspended in 50µl MeOH/CHCl3 2:1. Then, samples 
were re-extracted after addition of 50µl H2O. The organic phase was then recovered 
and analyzed by MS using the same settings as above. Spectra were obtained by 
Christer Ejsing. 
 
For MS analysis on the Orbitrap mass spectrometer, lipid extracts were obtained 
either 72h after siRNA transfection or 3.5h after addition of 10µM of a fatty acid, 
namely myristate, palmitate or oleate. Lipids were extracted using 100µl 
MeOH/CHCl3 5:1 and the extract was transferred to a 1.5ml Eppendorf tube 
(Eppendorf, Hamburg, Germany). 100µl of chloroform and 100µl H2O were added, 
tubes thoroughly vortexed and centrifuged at 1000g. The organic phase was 
transferred into a new tube and dried down in a SpeedVac. Samples were then 
resuspended in 100µl MeOH/CHCl3/isopropanol 2:1:4 supplemented with 7.5mM 
ammonium acetate. Mass spectrometric analysis was performed on a LTQ Orbitrap 
(ThermoElectron, San Jose, CA) equipped with a NanoMate HD robotic nanoflow 
ion source (Advion BioSciences Ltd, Ithaca, NJ) with 4.1µm nozzle diameter chip. 
NanoMate HD was operated in positive ion mode at an ionization voltage of 1.05kV 
and gas pressure of 1psi. MS/MS experiments on the LTQ Orbitrap were performed 
using collision-induced dissociation in the linear ion trap. Using QualBrowser 2.0 
software (ThermoElectron, San Jose, CA), each survey spectrum was converted into 
a peak list, which reported m/z, absolute intensity, relative intensity (normalized to 
the most abundant peak) and the sum composition for each peak detected with a 
signal-to-noise ratio above 6. The peak list was further imported by MarkerView 
software (MDS Sciex, Concord, Canada) for Principal Component Analysis (PCA). 
Spectra were obtained by Dominik Schwudke. 
 
 
RNA extraction and Real-Time PCR 
 
Cells in a 96 well-plate were rinsed with PBS and then resuspended in 100µl buffer 
RLT (Qiagen, Hilden, Germany). For each sample, lysates from three wells were 
pooled together. The lysate was then homogenized by centrifugation through a 
QIAshredder column (Qiagen, Hilden, Germany). RNA was isolated using the 
RNeasy kit  (Qiagen, Hilden, Germany) according to the manufacturers protocol. 
Finally, RNA was eluted in 30µl RNAse-free water (Qiagen, Hilden, Germany). To 
remove DNA contamination, 3µl 10x DNase buffer (0.4M Tris, 0.1M NaCl, 60mM 
MgCl2 in RNase-free water, pH 7.5) and 1µl RNase-free DNase I (10U/µl, Boehringer 
Ingelheim, Ingelheim, Germany) were added to the RNA solution and incubated at 
37°C for 30’, then at 65°C for 20’, cooled on ice and spun down. Then, 11µl RNA 
were heated to 70°C for 10’ to destroy secondary structure, cooled on ice for 2’ and 
spun down. For reverse transcription, 4µl reverse-transcriptase (RT) buffer 
(Promega, Mannheim, Germany), 0.4µl dNTP Mix (Fermentas, Burlington, Canada), 
0.6µl oligodT primers (Promega, Mannheim, Germany), 1µl RNAse inhibitor 
(Promega, Mannheim, Germany) and 2µl H2O were added to each sample. Before 
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adding the reverse transcriptase, 1µl was removed from each sample and mixed 
with 9µl H2O, to be used as a non-template control during Real-Time PCR. 1µl 
reverse transcriptase (Promega, Mannheim, Germany) was then added in each 
sample tube and reverse transcription was carried out at 37°C for 60’. 
 
For Real-Time PCR, 2,5µl cDNA were mixed with 2,5µl forward and reverse primer 
mix (1µM each) and 5µl SYBR green mix (ABgene, Hamburg, Germany). Primers are 
listed in table 2. Real-Time PCR was carried out on an Mx3000 instrument 
(Stratagene, Amsterdam, The Netherlands) using an annealing temperature of 60ºC. 
The house-keeping genes tubulin or GAPDH were used for normalization. 
 
 
SDS-page and western blotting 
 
After the addition of Laemmli sample buffer, samples were subjected to 3 cycles of 
heating at 95ºC for 5’ and sonication for 1’ in a Sonorex super 10P sonicator bath 
(Bandelin, Berlin, Germany). Samples were resolved by SDS-PAGE on mini-gels with 
various acrylamide percentages and then proteins were transferred from the gels 
onto nitrocellulose using a semi-dry blot system (Bio-Rad, Munich, Germany). 
 
Blocking was performed for 1h at room temperature or overnight at 4ºC in PBS or 
TBS supplemented with 0.2% Tween and 5% milk (Heirler, Radolfzell, Germany) or 
4% BSA (AppliChem, Darmstadt, Germany). Incubations with both primary and 
secondary antibodies were performed at room temperature for 2h and 1h 
respectively in the same solution as for the blocking. After each antibody incubation, 
blots were extensively washed in PBS or TBS supplemented with 0.2% Tween. 
Signal was detected using ECL or ECL+ (Amersham, Freiburg, Germany). 
 
 
Bodipy staining and microscopy 
 
4000 A431 cells were plated in 400µl growth medium in each well of a 24 well-plate 
20h before transfection. For each well, 14pmole siRNA were mixed with 100µl Opti-
MEM medium and 6µl Hiperfect (Qiagen, Hilden, Germany). The siRNA mix was 
incubated for 10’ to allow formation of the cationic liposome/RNA complex and then 
added to the cells. 48h after transfection, the growth medium was exchanged for 
growth medium supplemented with 20µM oleate or for DMEM supplemented with 
10% delipidated FCS. 72h after transfection, cells were rinsed once with PBS and 
fixed with 5% formaldehyde in PBS for 1h at room temperature. Cells were rinsed 
once again with PBS and Bodipy493/503 (MoBiTec, Götingen, Germany) was added 
to the cells at a final concentration of 2µg/ml. Staining was performed in the dark for 
1h at room temperature. After extensive rinses with PBS, cells were mounted on 
slides using 6µl Mowiol (CalBiochem, La Jolla, CA). Images were acquired on a 
Zeiss Axiovert 200 inverted confocal microscope (Jena, Germany) equipped with a 
63x Plan-Apochrom oil objective. Images were acquired by Julia Massier. 
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Material and Methods: Yeast cells 
 
 
Material 
 
Sty1 deletion strain of S. Pombe (JM1160, L972h- sty1::ura4 leu1-32 ura4-D18 ade6) 
and its parent wild-type strain (PR109, L972h- leu1-32 ura4-D18) were a kind gift 
from Dr. J. B. Millar. The wild-type strain L972h- and the strain expressing a GFP-
tagged C-truncated NADPH-reductase (PG 2747, CRL126 h90 leu1-32 ura4-D18 
ade6-216 D817GFP/Leu2) were a kind gift from Dr. I. M. Tolic-Nørrelykke. 
 
 
Yeast culture 
 
Yeast cells were grown in rich medium (YES) supplemented with 225mg/l uracil, 
adenine and L-leucine (Sigma, St. Louis, MO) (Forsburg & Rhind 2006), either on 
agar plate at 30ºC or in liquid cultures in a shaking incubator at 30ºC and 200rpm. 
 
 
Glucose depletion 
 
Yeast cells were grown till an optical density (OD) of 0.4 at 600 nm. Cell pellets were 
obtained by centrifugation, rinsed once with and re-suspended in either Edinburgh 
minimal medium (EMM2) supplemented with 225mg/l uracil, adenine and L-leucine 
(Sigma, St. Louis, MO) (Forsburg & Rhind 2006) or, for glucose-free conditions, in 
the same medium where glucose was replaced by the same quantity of sorbitol 
(Sigma, St. Louis, MO). Cells were further grown in these conditions for 1h. For lipid 
analysis by TLC, 1µCi/ml of 3H-oleate was added to the yeast sample during that 
time. 
 
 
Nile Red staining and microscopy 
 
Yeast cell pellets were obtained by centrifugation of 2ml culture, re-suspended in 
0.5ml PBS supplemented with 3µg Nile Red (Sigma, St. Louis, MO) and incubated 
10’ in the dark at room temperature and 1000rpm. Cells were rinsed twice in PBS 
and re-suspended in 200µl PBS. 2µl were used for microscopy. Images were 
acquired on an Olympus AX70 upright microscope (Hamburg, Germany) equipped 
with a 100x UplanApo oil objective and a CCD camera controlled with the Metavue 
software (Universal Imaging Corporation, Downingtown, PA).  
 
 
Lipid extraction and TLC 
 
Yeast cell pellets labeled with 3H-oleate were obtained by centrifugation of 5ml 
culture and rinsed twice in H2O. The pellets were then resuspended in 1ml 
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MeOH/CHCl3 2:1. Samples were homogenized by vigorous beating in the presence 
of glass beads (Sigma, St. Louis, MO) for 2’. After centrifugation, supernatant was 
transferred to a new tube with 400µl of 50mM citric acid and 600µl CHCl3. The 
organic phase was transferred to a new tube and evaporated under a stream of 
nitrogen. Lipids were then re-suspended in 30µl MeOH/CHCl3 2:1 and applied on 
the TLC plate using a capillary. Lipids were separated by TLC as described above. 
The TLC plate was then dipped in LumaSafe solution (Lumac LSC, Groningen, 
Netherlands) and exposed on MP films (Amersham, Freiburg, Germany) for 16h at -
80ºC. 
 
 
GFP fluorescence microscopy 
 
Lectin BS-I (Sigma, St. Louis, MO) was spread on a coverslip, which was then glued 
to the bottom of a microscopy dish. 5µl of yeast culture were added on the lectin 
and allowed to settle for 5’. Then the dish was filled with the appropriate culture 
medium. Images were acquired on a Zeiss Axioplan 2 MOT upright microscope 
(Jena, Germany) equipped with a 100x Plan Neofluar oil objective and a CCD 
camera controlled with the Metavue software (Universal Imaging Corporation, 
Downingtown, PA).  
 
 
Growth curve 
 
Cells were grown in the indicated medium and OD was measured at 600 nm on a 
Ultrospec 3100 pro spectrophotometer (Biochrom, Cambridge, United Kingdom) at 
various time points. When OD was above 1, yeast cultures were diluted 5x and the 
measured OD was then multiplied 5x to ensure linearity of the measurement. 
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The development of a method 
 
The initial step towards a better understanding of lipid homeostasis regulation is the 
identification of candidate genes implicated in this process. When absent or 
mutated, these genes would affect the lipid composition of a cell. Therefore, it was 
necessary to design a method that could monitor such changes. 
 
Systematic deletion or mutation in mammalian cells are still very demanding 
techniques, and are therefore not suitable for any large-scale analysis. More 
recently, the discovery of RNA interference (RNAi) (Elbashir et al 2001a, Fire et al 
1998), as a tool to specifically decrease the expression level of any gene, has 
opened new possibilities for large-scale analysis of gene function (Carpenter & 
Sabatini 2004, Dorsett & Tuschl 2004). 
 
Therefore, RNAi can be used to specifically knock-down a range of potential 
regulators of lipid metabolism. Subsequent analysis of lipid composition of the 
resulting knock-downs would allow the identification of genes affecting lipid 
homeostasis. 
 
Different methods can be used for subsequent lipid analysis. Among them, both the 
classical thin layer chromatography (TLC) technique and mass spectrometry (MS) 
were evaluated. 
 
 
RNA interference: A powerful tool 
 
Previously, post-transcriptional gene silencing in plants and quelling in fungi have 
shown the existence of a homology-based gene silencing mechanism in cells (Mol 
et al 1990, Romano & Macino 1992, Wassenegger et al 1994). However, the trigger 
of this process was not clear. In 1998, Fire et al. made a major observation, for 
which they were awarded the Nobel Prize last year. They realized that injection of 
long double-strand RNA (dsRNA) in C. elegans potently and specifically results in 
genetic interference with the corresponding gene (Fire et al 1998). These long 
dsRNA molecules are processed inside the cells to 21 nucleotides (nt) long small 
interfering RNA (siRNA), through the action of a ribonuclease type III enzyme called 
Dicer (Bernstein et al 2001). But, in mammalian system, long dsRNAs induce an 
interferon response, leading to unspecific inhibition of protein translation (Gil & 
Esteban 2000). However, in 2001, Elbashir et al. showed that direct introduction of 
chemically synthesized siRNAs bypasses the interferon response, promoting 
specific knock-down of the targeted gene (Elbashir et al 2001a). 
 
Once in the cell, the siRNA molecules are incorporated into a RNA-induced silencing 
complex (RISC) (Hammond et al 2000). This complex is able to recognize the 
perfectly matching messenger RNA (mRNA) and to induce the cleavage of that 
molecule (Elbashir et al 2001b, Hammond et al 2000), thereby impairing expression 
of the corresponding gene. 
 41 
RNA interference applied to the study of lipid metabolism 
 
SiRNAs are 21 nt dsRNA duplexes that contain 2 nt overhangs with a 5’-phosphate 
and a 3’-hydroxyl termini (Elbashir et al 2001b). These features are characteristic of 
the cleavage by an RNAseIII enzyme, like Dicer, and are required for proper 
recognition by the RISC complex (Ma et al 2004, Ma et al 2005, Parker et al 2005). A 
(almost) perfect complementarity to their target sequence is necessary to induce 
mRNA cleavage. However, different sequences targeting a same gene can have 
different effectivity (Harborth et al 2001, Harborth et al 2003, Holen et al 2002), and 
although some characteristics have been linked to better silencing efficiency (Mittal 
2004, Reynolds et al 2004), this variation is still not fully understood. It is therefore 
often necessary to test several siRNAs differing in sequence to find a potent one. An 
alternative is to use a mix of enzymatically-processed siRNAs, which are formed by 
in vitro-cleavage of long dsRNAs by Dicer (Kawasaki et al 2003, Myers et al 2003) or 
E.coli RNAseIII enzymes (Yang et al 2002a). 
 
In this study, both chemically synthesized and RNAseIII-processed siRNAs were 
used. The RNA interference process was coupled to the analysis of lipid 
composition. The general scheme of the method is shown in figure 11. A more 
detailed description of its optimization can be found below. 
 
 
Figure 11: Schematic representation of the method. 
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SiRNAs can be delivered into cells via lipophilic transfection or via electroporation. 
However, on basis of previous experience from colleagues and robotic limitations in 
case of large-scale studies, the lipophilic transfection reagent oligofectamine was 
selected. Hela cells were used as a model cell line, because of its recognized ease 
of transfection, an important factor for large-scale analysis. 
 
The efficiency of the knock-down depends not only on the mRNA degradation as 
such, but also on the turnover of the already existing proteins. Therefore, effective 
knock-down of a protein may require 72h (Elbashir et al 2002, Jackson et al 2006). 
Therefore, this time point was selected for harvesting the cells for lipid analysis. 
 
To promote lipid synthesis, cells are placed in lipid-free condition 24 hours before 
harvesting. This is achieved by the use of a growth medium containing delipidated 
FBS (Thiele et al 2000). 16 hours before harvesting, radioactive acetate is added into 
the wells. Acetate is the building block of all the major lipids in the cell (figure 12). 
The use of radioactive acetate therefore results in labeling of all newly synthesized 
lipids. 
 
Figure 12: Incorporation of acetate into cholesterol. 
The red and green carbon atoms depicted in the molecule of cholesterol are derived through 
biosynthesis from the carbon atom depicted in the same color in the acetate molecule. 
 
At the time point of harvesting, cells are rinsed and lipids are directly extracted 
using a one-phase system. Different compositions of the extraction solution were 
tested, namely MeOH, MeOH/CHCl3 5:1 and MeOH/CHCl3 3:1. As shown in Fig. 3.3, 
no major difference in efficiency was observed using either MeOH or MeOH/CHCl3 
5:1 for the lipid extraction. The use of a higher ratio of CHCl3 however decreased the 
efficiency of the extraction. In addition, the one-phase method was compared to the 
classical ‘Bligh and Dyer’ two-phases lipid extraction system (Bligh & Dyer 1959), 
and again no significant difference was observed. The influence of increasing 
amount of radioactive acetate on the staining was also tested. Although labeling 
with 1µCi/well gives a weaker staining, similar output signals were obtained using 
2µCi or more (figure 13). Therefore, addition of 2µCi 14C-acetate per well, and a one-
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phase lipid extraction, namely MeOH/CHCl3 5:1, were chosen to obtain the best 
lipid signal. 
 
 
 
Figure 13: Test of extraction and labeling conditions. 
14C-labeled lipids from Hela cells were extracted using MeOH (lane 1-4), MeOH/CHCl3 5:1 
(lane 5-8) and MeOH/CHCl3 3:1 (lane 9-12) after labeling with various amounts of 
radioactivity (1µCi in lanes 1, 5 and 9, 2µCi in lanes 2, 6 and 10, 3µCi in lanes 3, 7 and 11 
and 4µCi in lanes 4, 8 and 12). Signal was visualized upon exposure on phosphoimager 
plate. 
 
The lipid extracts are then separated on a TLC plate using a two-solvent system as 
described previously (Kuerschner et al 2005). However, to improve the separation of 
the different classes of phospholipids, the possibility to increase the hydrophilicity of 
the first solvent was tested (data nor shown). The chosen composition was finally 
EtOH/H2O/triethylamine/CHCl3 50:10:35:35. To further improve the resolution, high 
1 3 4 5 6 2 
2 
7 8 9 10 12 11 
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performance TLC (HPTLC) plates or pre-concentrative migration were tested, but no 
convincing results were obtained. 
 
To identify the different lipid bands and further confirm that this system allows good 
separation of all the major lipid classes, standards of these lipids were run in this 
system and their migration was compared with the Hela cells lipid extract (figure 14). 
 
In the case of acetate labeling, the radioactive signal can be visualized upon 
exposure on a phosphoimager plate. Then, a lipid intensity profile of the different 
lanes is obtained. Thanks to the software Graph Explorer developed in-house by 
Yannis Kalaidzidis (Kalaidzidis et al 1997), it is now possible to directly compare 
profiles or quantify the individual bands. Conversely to previously existing 
quantification programs, the lipid bands are fitted with Gaussian curves, taking into 
account the overlapping of different classes of lipids that are insufficiently resolved 
by the chromatography itself. This therefore strongly improves the reliability of the 
results. However, attempts to automate the quantification procedure were 
unsuccessful, limiting the use of quantification to the analysis of a small number of 
samples. 
 
Finally, the effect of the transfection reagent on lipid composition was also tested. 
The lipid composition of wild type untreated cells or cells treated with 
oligofectamine were compared using both TLC and MS analysis. A similar lipid 
pattern was observed by TLC for both untransfected and mock-transfected cells 
(figure 16, lanes 1 and 15). For the MS analysis, untransfected and mock transfected 
cells were compared to cells treated with siRNA inducing a known change in lipid 
composition, as determined previously by TLC (data not shown). The MS analysis 
was performed by Dominik Schwudke and the MS data were then processed by 
Principal Component Analysis (PCA) as described previously (Schwudke et al 2007). 
As it can be seen in the PCA plot (figure 15), the mock transfected and 
untransfected samples, as well as the samples treated with a siRNA which didn’t 
induce any change in lipid composition cluster together, while the siRNA inducing 
either an increase in SM or an increase in TAG are found in a completely different 
area of the plot. This confirms by an independent method that no major change in 
lipid composition is induced by the oligofectamine treatment, confirming that this 
transfection reagent can be used despite its lipidic nature. 
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Figure 14: TLC with standard lipids. 
Different standard lipids indicated in the picture were applied on a TLC plate and submitted 
to our two-solvents running system. Their migration can be compared to the corresponding 
bands in the Hela cells lipid extracts (the two first lanes of each plate) in order to identify the 
nature of the different lipids separated by this system. Lipids were visualized by charring 
with H2SO4. 
PC SM PS PE PI LPA PA 
GlcCer GalCer Cer CL DAG Chol CE TAG 
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Figure 15: Effect of oligofectamine on lipid composition as determined by MS. 
(a) The PCA plot was build on the basis of the individual mass signals obtained during the 
MS experiment. A2/3: untreated cells, B2/3: mock transfection. C2/3: siRNA inducing an 
increase in SM, D2/3: siRNA inducing no lipid modification, D4/5: siRNA inducing an 
increase in TAG. 
(b) Loading plot: each chemical formula stands for the corresponding lipid species, and 
inform on its weight in the positioning of the samples into the PCA plot. 
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Finding the controls 
 
Appropriate controls are essential in the design of large-scale experiments. As 
negative controls, mock transfection was used as well as transfection with siRNA 
that would not target any gene in the genome, like F-luciferase, neomycin or the 
scrambled silencer siRNAs S2, S5 and S6. 
 
As a positive control to test transfection efficiency, the previously characterized Eg5 
gene was selected (Harborth et al 2001, Weil et al 2002). This gene encodes for a 
kinesin related protein implicated in mitosis. Upon knock-down, cells arrest in 
mitosis, and ultimately die. This results in the round appearance of the cells and, on 
a TLC plate, in the absence of radioactive signal. 
 
To find appropriate positive controls related to lipid metabolism, enzymes of the 
lipid biosynthetic pathway were analyzed. For this purpose, endoribonuclease-
prepared siRNA (esiRNA) (Yang et al 2002a), derived from a library generated by 
Ralf Kittler (Kittler & Buchholz 2003), were used. In brief, cDNA clones were used as 
a starting material, from which dsRNAs were generated and then cleaved in small 
fragments by E.coli RNAseIII. 
 
Among all the proteins tested, only the knock down of the sterol O-acyl transferase 
(SOAT1) was inducing a visible phenotype. SOAT1, sometimes better known as 
Acyl-Coa:cholesterol acyltransferase (ACAT1), is responsible for the esterification of 
cholesterol. Knock-down of this gene effectively induces a decrease in cholesterol 
ester level (figure 16). 
 
Further quantification of the lipid profiles generated by the different knock-downs 
demonstrates that upon esiRNA treatment against the PI synthase, a small decrease 
in PI level is also observed (figure 17).  
 
Although phenotypes could have been expected for other knock-downs, there may 
be several possible explanations. First, this can result from a poor effectiveness of 
some of the esiRNAs, or a slow turnover of the corresponding protein. In addition, 
as most of the genes tested were enzymes, a small quantity of protein left could be 
sufficient to perform its function and maintain lipid homeostasis (Harborth et al 
2001). Furthermore, redundancy in the lipid biosynthetic pathway could also 
account for absence of phenotype in some knock-downs. 
 
 
 48 
 
 
Figure 16: TLC analysis of lipid extracts of esiRNA knock-downs. 
14C-labeled lipid extracts from Hela cells treated with esiRNA against the following genes: 
(1) no transfection, (2) SOAT1, (3) FATP3, (4) FATP5, (5) mevalonate kinase, (6) DGAT2, (7) 
squalene synthase, (8) PI synthase, (9) SPT2, (10) CTP-cytidyltransferaseB, (11) SPT1, (12) 
Eg5, (13) F-luc, (14) R-luc, (15) mock transfection. The positions of the different lipid classes 
on the plate are indicated on the right of the plate. Radioactive signal was visualized upon 
exposure on phosphoimager plate. 
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Figure 17: Decrease of PI levels in the PI knock-down. 
Upon Gaussian fitting of the lipid profiles, the percentage of PI relative to the total amount of 
lipid was determined for the PI synthase knock-down and compared to mock transfection, 
the negative control F-luciferase and the knock-down of the unrelated enzymes DGAT2 and 
SOAT1. 
 
 
Signal normalization 
 
SiRNA transfection can induce toxicity and thereby cell death. To be able to 
compare the lipid signal of different samples, normalization is necessary. In case of 
complete quantification of the profiles, normalization to total lipid signal was 
achieved. However, this requires fitting of all the bands and is therefore not 
appropriate for large-scale analysis. To overcome this problem, normalization was 
done to the most abundant lipid, PC, for profile comparisons. From the initial 
studies, PC appeared to be less subject to level variation than some other lipids. 
Furthermore, variation in PC would still be visible by the resulting increase or 
decrease in all the other lipid classes after normalization. 
 
This normalization method however limits the observations to variations in the level 
of specific lipids and modification of total lipid synthesis or degradation would not 
be detectable. Normalization to the cell number could overcome this limitation. 
Therefore, several protein quantification tools were evaluated for use directly in the 
wells after lipid extraction. However, this often led to interference with the SDS used 
to redissolve the protein (for the Bradford assay), or to an overestimation of protein 
levels at low cell numbers (for the BCA and fluorescamine assays). This effect is 
probably due to the presence of bovine serum albumin (BSA) in the serum. Because 
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of its hydrophobicity, BSA easily sticks to the walls of the wells and thereby impairs 
cellular protein determination. 
 
Better results however were obtained using propidium iodide to evaluate the total 
DNA content of a well (figure 18). A linear signal could be obtained after long 
incubation of the dye with the cells to allow saturation of the signal. Although this 
method was not precise enough to normalize the lipid signal, it could be used to 
identify strong variation in total lipid synthesis upon specific knock-down. 
 
 
Figure 18: Propidium iodide fluorescence intensity in function of the number of cells plated. 
Cells were plated 16h before measurement. Fluorescence intensity was measured at 620 nm 
at different time points. Linearity was observed after 3h or 6h of incubation with the dye. 
 
 
Mass spectrometry: An alternative method to study lipid composition 
 
In the past few years, mass spectrometry appeared as a powerful tool to study 
biological molecules. Proteomics efficiently used this technique to decipher the 
protein content of specific cells or organelles (Peng & Gygi 2001). More recently, 
there has been a rising interest in the use of mass spectrometry as a tool to analyze 
lipid composition (Brugger et al 1997, Han & Gross 2003, Schneiter et al 1999). The 
potential of this method to study the lipid composition of the knock-downs was 
therefore investigated. 
 
While TLC analysis is limited to the study of newly synthesized lipids that have been 
labeled with radioactive acetate, MS doesn’t require any labeling and generate 
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therefore a profile of all the lipids present in a sample at a given time point. In 
addition, MS analysis enables not only identification of the different lipid classes but 
distinguishes between several species differing by their fatty acid composition and 
therefore by their mass. This allows therefore a more precise overview of the lipid 
composition of a sample. However, since several species from different classes may 
have very similar masses (Schwudke et al 2007), there may be some uncertainty on 
the nature of certain lipid peaks, which could only be revealed by further 
fragmentation of these lipids and subsequent MS analysis, a method known as 
MS/MS. Nevertheless, the use of mass spectrometer with high mass accuracy, such 
as the Orbitrap instrument (Hu et al 2005), partially overcomes this problem 
(Schwudke et al 2007). The other limitation of mass spectrometry is the difficulty to 
analyze neutral lipids, like sterols, which are of major importance in cells. This can 
be overcome by derivatisation (Liebisch et al 2006), a process that adds a charge to 
the molecule. However, this is difficult to perform in the context of the analysis of a 
large number of samples and limits therefore large-scale lipid analysis by MS to the 
study of charged lipids. 
 
Therefore TLC analysis and mass spectrometry can be viewed as complementary 
techniques in the generation of the lipid profile of biological samples. 
 
So far, large-scale analysis by mass spectrometry was limited by the manual 
injection of the sample in the electrospray ion source. However, the introduction of 
the robotic nanoflow ion source Nanomate, which allows automatic injection of 
samples from a 96 well-plate, increases the potential of this technique for large-
scale analysis (Schultz et al 2000). 
 
To evaluate the potential of the method in the context of the screening procedure 
developed above, lipid extracts generated by one-phase extraction of Hela cells in 
96 well-plate were applied to MS analysis on a Esi-QqTof mass spectrometer 
(Chernushevich et al 2001). Unfortunately, as shown in figure 19 a, this gave rise to 
very noisy spectra, probably due to the concomitant extraction of a large number of 
compounds generally removed by a two-phase extraction. Accordingly, spectra 
generated after two-phase extraction of the same sample contain much less 
contaminating peaks (figure 19 b.). More hydrophobic extraction solutions were 
further tested, to limit the extraction of some contaminating hydrophilic compounds, 
but this didn’t improve sufficiently the quality of the spectra (data not shown). The 
use of MS analysis was therefore limited for this study to the characterization of 
samples that would be selected after TLC analysis. 
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Figure 19: Esi-MS analysis of lipid extracts from Hela cells obtained either by (a) one phase 
lipid extraction in a well of a 96 well-plate using MeOH/CHCl3 2:1 supplemented with 5 mM 
ammonium acetate or (b) after subsequent addition of water and two-phase extraction of the 
same sample. Spectra were generated by Christer Ejsing on a Esi-QqTof mass 
spectrometer. 
 
MS spectra enable identification of a large number of individual species, and, as a 
result, give rise to a large number of data. It is therefore wise to simplify the dataset 
in order to identify variation in lipid composition between several samples. To do so, 
Schwudke et al. developed a method based on principal component analysis (PCA) 
(Schwudke et al 2007). Briefly, this method reorganizes the individual variables – 
here the signal of each individual mass – into a new set of variables called principal 
components. By giving different weight to each original variable, the method can 
extract similarities and differences between the samples. The first principal 
components (PC1 and PC2) will thereby contain the information on the major 
differences between the samples. These samples can then be plotted in function of 
their principal components. Samples of similar lipid composition will then be found 
in the same area of the PCA plot, while samples having a different lipid composition 
will be located somewhere else. The PCA loading plot informs on the influence of 
lipid species of a given mass to the position of a sample on the PCA plot. Thereby, 
one can find back which lipids may be responsible for the difference. 
 
The method was tested by analyzing perturbations of the lipidome of Hela cells 
upon addition of specific fatty acids in the cell culture medium. Then, the samples 
were analyzed by MS on a LTQ-orbitrap mass spectrometer (Hu et al 2005) by 
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Dominik Schwudke and the resulting data sets, comprising 262 mass signals, were 
submitted to PCA analysis (figure 20). Using the PCA loading plot, it is possible to 
identify the lipid species of a given mass whose intensity was specifically modified 
in the different samples. Further MS/MS analysis of the corresponding peaks 
confirmed that addition of myristate, palmitate or oleate specifically induce an 
increase in the PC and TAG species harboring the corresponding fatty acid (table 3). 
 
 
Figure 20: Principal Component Analysis (PCA) of 262 individual mass detected in HeLa cells 
feeding experiments. 
(A) PCA plot (B) PCA loading plot. M1, M2 stand for two independent experiments with 
addition of myristic acid; O1, O2: of oleic acid; P1, P2: of palmitic acid; C1, C2: controls, no 
extra fatty acid added. 
 
This method appears therefore as a good tool to characterize the variation in lipid 
composition that can arise from RNA interference of certain genes and can be 
utilized for secondary analysis of potential hits. 
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Table 3: Lipid species whose abundance was specifically increased by spiking fatty acids, as 
revealed by Principle Component Analysis. M1, M2 myristic acid added (FA 14:0); O1, O2 
oleic acid added (FA 18:1); P1, P2 palmitic acid added (16:0), C1, C2: controls. Relative 
intensities are presented in percentage normalized to the most abundant lipid sum 
composition C42H83O8N1P1, subsequently identified as PC 34:1. 
 
m/z Sum Composition Lipid M1 M2 O1 O2 P1 P2 C1 C2 
706.5389 
C38 H77 O8 N1 
P1 PC 14:0/16:0 54.3 50.7 13.7 13.4 14.1 14.1 15.7 16.1 
704.5237 
C38 H75 O8 N1 
P1 PC 14:0/16:1 7.9 7.3 2.0 2.0 1.7 1.8 2.5 2.6 
678.5079 
C36 H73 O8 N1 
P1 PC 14:0/14:0 13.3 10.8 0.6 0.5 0.4 0.5 0.7 0.7 
794.7240 C49 H96 O6 N1 
TAG 14:0/14:0/18:1; 
TAG 14:0/16:0/16:1 6.5 4.3 0.2 0.2 0.5 0.3 0.1 0.1 
           
786.6007 
C44 H85 O8 N1 
P1 PC 18:1/18:1 45.0 44.3 54.2 54.6 39.5 41.1 45.1 44.7 
902.8182 C57 H108 O6 N1 TAG 18:1/18:1/18:1 1.4 1.4 12.3 14.3 1.9 2.6 2.3 1.9 
876.8024 C55 H106 O6 N1 TAG 16:0/18:1/18:1 3.3 3.1 10.1 11.6 5.6 6.6 3.9 3.2 
            
734.5696 
C40 H81 O8 N1 
P1 PC 16:0/16:0 34.2 35.8 32.8 31.5 53.3 46.6 37.4 37.7 
824.7708 C51 H102 O6 N1 TAG 16:0/16:0/16:0 1.2 0.9 0.2 0.2 4.6 3.1 0.4 0.3 
850.7866 C53 H104 O6 N1 TAG 16:0/16:0/18:1 3.3 2.8 2.2 2.4 7.9 7.1 1.6 1.4 
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The Kinase Screen 
 
After development of the method, it was possible to apply it to the study of protein 
families whose members could potentially be implicated in lipid homeostasis. 
Kinases have been previously implicated in the regulation of numerous processes 
and appear therefore as obvious candidates in the study of lipid regulation.  
 
SiRNA libraries against kinases have been developed and made commercially 
available. The siRNA library used was designed by Ambion and targets 600 kinases, 
each of them with three siRNA sequences. Individual siRNA sequences vary in 
efficiency in a manner not yet fully understood. In order to ensure a sufficient 
efficiency for each kinase, the screen was performed using a pool of the three 
individual sequences, hypothesizing that at least one of them would be sufficiently 
potent to reach a good knock-down efficiency. 
 
 
The preparation of the screen 
 
Because of the large number of samples, the screen was performed in collaboration 
with the Technology Development Studio (TDS), using their robotic equipment for 
transfection. 
 
Since the method was initially developed using esiRNAs, the reproducibility of the 
positive control SOAT1 was tested using siRNAs. The efficiency of the knock-down 
was monitored by Real-Time PCR using either individual siRNA or a pool of the 
three sequences available. The best knock-down efficiency was obtained using the 
siRNA pool, although the individual sequence 1 was much less efficient than the two 
others (figure 21). Then, the potency of these siRNAs to decrease cholesterol ester 
level was tested by TLC. Both the individual sequence 2 and the pooled sequences 
gave rise to a strong decrease in cholesterol esters, while the individual sequences 
1 and 3 induced only a moderate decrease (figure 22). Taken together, these results 
confirm that the use of a pool of individual sequences ensures a good knock-down 
efficiency without need for testing individual sequences. 
 
As a last control, SOAT1 mRNA level and cholesterol ester level were monitored 
after robotic transfection for the negative control S2 and the positive control SOAT1. 
Similar results as for manual transfection were obtained (results not shown), 
confirming that robotic transfection was suitable for our assay. 
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Figure 21: Decrease in SOAT1 mRNA level upon siRNA treatment. 
Percentage of SOAT1 mRNA level left 72h after siRNA treatment in the siRNA knock-downs 
relative to mock transfection and neomycin siRNA negative controls. Values are normalized 
to tubulin mRNA level to account for variation of total mRNA. Error bars represent standard 
deviation. 
 
 
 
Figure 22: Decrease of cholesterol esters upon SOAT1 siRNA knock-down. 
(a) Close-up on the 14C-labeled storage lipids on a TLC. Lipids were extracted 72h after 
transfection for the following samples: no transfection (1), mock transfection (2), or treatment 
with siRNA against eg5 (30nM) (3), neomycin (30nM (4) or 60nM (5)) and SOAT1 (pool (30nM 
(6)), pool (60nM (7)), sequence 1 (60nM (8)), sequence 2 (60nM (9)) and sequence 3 (60nM 
(10))). (b) Ratio between cholesterol ester and triglyceride levels after normalization to non-
transfected samples. Error bars represent standard deviation. 
 
CE 
TAG 
 1      2     3     4     5  6     7   8     9    10 
A 
B 
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The Screen 
 
A screen targeting 600 human kinases was performed in Hela cells in duplicates 
using a pool of three siRNAs per gene. The screen was carried out in a 96 well-plate 
format, although only the 60 internal wells of the plates were used to avoid 
unspecific effects related to medium evaporation in the external wells. 
 
The transfection was performed following the scheme shown in figure 23. Although 
most of the wells were transfected with siRNAs against kinases, each row contained 
either a well transfected with the pool of SOAT1 siRNAs, used as positive control, or 
a well mock-transfected as negative control. This ensures that each TLC plate 
contains a positive and a negative control. In addition, several wells dispersed in the 
plates were transfected either with the positive control eg5 or with the negative 
control S2. 
 
In addition, the number of cells in each well was evaluated by fluorescent 
measurement using propidium iodide, in order to take into account cell death and 
variation in cell growth after the siRNA treatment. 
 
Lipid extracts from the siRNA transfected cells were then separated by TLC. A 
sample TLC plate is shown in figure 24. Such plate contains both the positive 
control SOAT1 and the negative mock transfection control (figure 24, lane b and c 
respectively). The other samples are derived from the kinase knock-downs. Out of 
the 600 kinases, 35 were identified whose knock-down induces a modification of 
lipid composition readily visible on the TLC plate. Mostly, the level of cholesterol or 
triglyceride was affected in these knock-downs. Further analysis of the different 
knock-downs was achieved by comparison of the lipid profiles. This extended the 
number of gene knock-downs inducing a phenotype to 91. 
 
Using the program CUPID, the kinases were clustered in function of the 
modifications of their lipid profiles (figure 25). Thereby, 10 phenotypic classes 
characterized by their lipid phenotype could be identified. It must be noted that no 
correlation was observed between the kinase groups generated by the clustering 
and the kinase families shown in the same color in figure 23. This suggests that 
different members of a same family of kinases are implicated in different biological 
processes, while several kinases from different families can act together or 
independently in a specific regulation process. 
 58 
 
Figure 23: Plate layout for the siRNA transfection of the kinase screen. 
Kinases are depicted in different colors in function of protein families. Black and white wells 
are used for the controls. 
AGC-CAMK-R1
1 2 3 4 5 6 7 8 9 10 11 12
A
B GPRK7 HSA250839 LATS1 LATS2 MAST205 MGC23665 CDC42BPA PDPK1 pknbeta SOAT
C PRKCA PRKCB1 PRKCD PRKCE PRKCG PRKCI PRKCL1 PRKCL2 PRKCQ mock
D PRKX PRKY RHOK ROCK1 ROCK2 RPS6KA1 RPS6KA2 RPS6KA3 RPS6KA4 SOAT
E RPS6KB2 RPS6KC1 RPS6KL1 SGK SGK2 SGKL STK38 STK38L PRKCH mock
F ARK5 C20orf97 C8FW CAMK1 CAMK1G CAMK2A CAMK2B CAMK2D CAMK2G SOAT
G CKLiK DAPK1 DAPK2 DAPK3 DCAMKL1 GS3955 HUNK KIAA0999 KIAA1811 mock
H
AGC-CAMK-GO1-R2
1 2 3 4 5 6 7 8 9 10 11 12
A
B GPRK6 ADRBK1 MAPKAPK3 CDC42BPB MELK PRKACA PRKACB CHK ADK SOAT
C PRKACG ADRBK2 MAPKAPK5 DMPK MGC42105 PRKCZ PRKG1 DGKI AK1 mock
D PRKG2 AKT1 MARK1 FLJ14813 MGC45428 RPS6KA5 RPS6KA6 FLJ13052 AK3 SOAT
E RPS6KB1 AKT2 MARK2 FLJ25006 MGC8407 NM_007174 eg-5 HK1 AK3L1 mock
F APEG1 AKT3 MARK3 GPRK2L MKNK1 CAMK4 CASK MGC26597 AK5 SOAT
G CHEK2 CDC42BPA MARKL1 GPRK5 MKNK2 LOC283629 MAPKAPK2 NYD-SP15 C9orf12 mock
H
CMGC-CAMK-R3
1 2 3 4 5 6 7 8 9 10 11 12
A
B CDK9 CDKL1 CDKL2 CDKL3 CDKL5 CLK1 CLK2 CLK3 CLK4 SOAT
C DYRK2 DYRK3 DYRK4 ERK8 FLJ32818 GSK3A GSK3B HIPK2 HIPK3 mock
D MAPK1 MAPK10 MAPK11 MAPK12 MAPK13 MAPK14 MAPK4 MAPK6 MAPK7 SOAT
E PCTK1 PCTK2 PFTK1 PRPF4B RAGE SRPK1 STK23 SRPK2 CDK11 mock
F MYLK2 PASK PHKG1 PHKG2 PIM1 PIM2 PRKAA1 PRKAA2 PRKCM SOAT
G PSKH2 SNARK SNF1LK SNRK SSTK STK17A STK17B STK22B STK22C mock
H
CMGC-CAMK-GO1-R4
1 2 3 4 5 6 7 8 9 10 11 12
A
B CDK8 ALS2CR7 STK33 CDK2 MGC4796 CRK7 DYRK1A DGKE DGKG SOAT
C DYRK1B CCRK TRAD CDK3 LOC91807 ICK LOC51701 FLJ12171 FLJ12476 mock
D MAK CDC2 TRIO CDK4  --- MAPK8 MAPK9 GNE GUK1 SOAT
E Nbak2 CDC2L1 TTN CDK5 S2 eg-5  --- KIAA0626 LCK mock
F MYLK CDC2L5 CHEK1 CDK6 S2 PRKCN PRKD2 NME4 NME7 SOAT
G PSKH1 CDK10 STK11 CDK7 eg-5 STK22D STK29 PFKFB3 PFKFB4 mock
H
GO1-R5
1 2 3 4 5 6 7 8 9 10 11 12
A
B CKB CKM CKMT1 CKMT2 CSS3R DCK DGKA DGKB DGKD SOAT
C DGKQ DGKZ DGUOKDKFZP586B1621DTYMK EKI1 FLJ10761 FLJ10842 FLJ11149 mock
D FLJ22055 FLJ32704 FN3K FUK GALK1 GALK2 GCK GK GK2 SOAT
E HK2 HK3 IHPK1 IHPK3 ITPK1 ITPKA ITPKB ITPKC KHK mock
F MGC26954 MRC2 MVK NAGK NBP NM23-H6 NME1 NME2 NME3 SOAT
G NYD-SP25 P15RS PACSIN1 PANK1 PAPSS1 PAPSS2 PDXK PFKFB1 PFKFB2 mock
H
Other-GO1-R6
1 2 3 4 5 6 7 8 9 10 11 12
A
B EIF2AK3 ERN1 ERN2 FLJ10074 FLJ20335 FLJ20574 FLJ23356 FLJ32685 GAK SOAT
C GUCY2F HRI IKBKE KIS LOC149420 MGC16169 MOS NEK11 NEK2 mock
D NEK7 NEK9 NPR1 NPR2 NRBP PACE-1 PIK3R4 PINK1 PKMYT1 SOAT
E PRKWNK4 RNASEL SCYL1 SDCCAG43 SNK STK12 STK13 STK16 STK18 mock
F STK6 TBK1 TEX14 TLK1 TLK2 TOPK TTK ULK1 ULK2 SOAT
G CALM3 CARKL CDK5R1 CDKN1A CDKN3 CERK S2 eg-5 eg-5 mock
H
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Figure 23: Plate layout for the siRNA transfection of the kinase screen (continued). 
Other-CK1-R7
1 2 3 4 5 6 7 8 9 10 11 12
A
B CSNK2A2 AAK1 CSNK1A1 CAMKK1 LOC51231 GSG2 GUCY2C S2 eg-5 SOAT
C GUCY2D ASB10 CSNK1D CAMKK2 MGC33182 NEK3 NEK4  ---  --- mock
D NEK6 BIKE CSNK1E CDC7L1 TTBK PLK PRKR S2 eg-5 SOAT
E PRKWNK1 BUB1 CSNK1G1 CHUK VRK1 STK31 STK35  ---  --- mock
F STK36 BUB1B CSNK1G2 CNK VRK2 WEE1 NEK8 S2 eg-5 SOAT
G PRKWNK3 C20orf64 CSNK1G3 CSNK2A1  ---  ---  ---  ---  --- mock
H
STE-Atyp-R8
1 2 3 4 5 6 7 8 9 10 11 12
A
B MAP3K4 MAP3K5 MAP3K6 MAP3K8 MAP4K1 MAP4K2 MAP4K3 MAP4K4 MAP4K5 SOAT
C MYO3B OSR1 PAK1 PAK2 PAK3 PAK4 PAK6 SLK STK10 mock
D STK39 STK4 TAO1 PAK7 MAP2K7 S2 eg-5 S2 eg-5 SOAT
E ATM ATR BCKDK BCR BRD2 BRD3 BRD4 BRDT CABC1 mock
F FLJ12229 FRAP1 H11 HAK LAK LOC203054 LOC57143 MGC20727 MIDORI SOAT
G PDK4 PRKDC PTK9 PTK9L SMG1 STK19 SUDD TAF1 TAF1L mock
H
STE-Atyp-TK-R9
1 2 3 4 5 6 7 8 9 10 11 12
A
B MAP3K3 ALS2CR2 TRIM33 MAP2K3 MINK MST4 p761P1010 ABL1 S2 SOAT
C MYO3A FLJ23074 TRPM6 MAP2K4 STK24 STK25 EPHB4 ABL2 eg-5 mock
D STK3 FLJ90524 TRPM7 MAP2K5  ---  --- FLT3 ACK1 S2 SOAT
E AD034 JIK TRRAP MAP2K6 EEF2K FASTK KIT ALK eg-5 mock
F FLJ11159 MAP2K1  --- MAP3K14 PDK1 PDK2 PDGFRA AXL S2 SOAT
G PDK3 MAP2K2  --- MAP3K2 TIF1 TRIM28 SRMS BLK eg-5 mock
H
TK-R10
1 2 3 4 5 6 7 8 9 10 11 12
A
B EGFR EPHA1 EPHA2 EPHA3 EPHA4 EPHA5 EPHA7 EPHA8 EPHB1 SOAT
C EPHB6 ERBB2 ERBB3 ERBB4 FER FGFR1 FGFR2 FGFR3 FGFR4 mock
D FLT4 FRK FYN HCK IGF1R INSR ITK JAK1 JAK2 SOAT
E KPI2 LTK LYN MATK MERTK MET MST1R MUSK NTRK1 mock
F PDGFRB PTK2 PTK2B PTK6 PTK7 RET ROR1 ROR2 ROS1 SOAT
G SYK TEC TEK TIE TNK1 TXK TYK2 TYRO3 YES1 mock
H
TKL-GO2-R11
1 2 3 4 5 6 7 8 9 10 11 12
A
B FLJ23119 FLJ25965 FLJ34389 ILK IRAK1 IRAK2 IRAK3 IRAK4 KIAA1804 SOAT
C MAP3K10 MAP3K11 MAP3K12 MAP3K13 MAP3K7 MASL1 RAF1 RIPK1 RIPK2 mock
D TGFBR1 TGFBR2 ZAK Ksr ANKK1 S2 eg-5 S2 eg-5 SOAT
E PFKM PFKP PGK1 PGK2 PI4K2B PI4KII PIK4CA PIK4CB PIP5K1A mock
F PKD2 PKLR PKM2 PMVK PNKP PRKAR2A PRKRA PRP4 PRPS1 SOAT
G SPHK1 SPHK2 SPS SPS2 TK1 TK2 TPK1 UCK1 UGP2 mock
H
TKL-GO2-TK-R12
1 2 3 4 5 6 7 8 9 10 11 12
A
B BRAF ACVR1 URKL1 AMHR2 LIMK1 LIMK2 BMX EPHB2 EPHB3 SOAT
C LOC51086 ACVR1B XYLB ANKRD3 RIPK3 TESK1 BTK FGR FLT1 mock
D TESK2 ACVR2 ZAP70 ARAF1 S2 eg-5 CSF1R JAK3 KDR SOAT
E PFKL ACVR2B  --- BMPR1A PIP5K2A PIP5K2B CSK NTRK2 NTRK3 mock
F PK428 ACVRL1 S2 BMPR1B PRPS2 PYCS DDR1 RYK SRC SOAT
G RBSK ALK7 eg-5 BMPR2 UMP-CMPK UMPK DDR2 FES INSRR mock
H
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Figure 24: Typical TLC plate from the screen. 
This plate corresponds to the samples from rows B and C of the 5th 96 well-plate (see figure 
23). Each vertical lane corresponds to the lipid extract of a kinase or control knock-down. 
Lipids were separated on the TLC and the positions of the different lipid classes on the plate 
are indicated on the right of the plate. 14C-labeled lipids were visualized upon exposure on a 
phosphorimager plate. Specific lanes are denominated with letters: (a) CSS3R knock-down, 
(b) SOAT1 knock-down, (c) mock transfection. 
SM PC 
GM3 
PI PE 
CL, PG, 
GlcCer 
Chol DAG 
TAG CE 
Cer 
A B C 
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Figure 25: Clustering of the phenotypic lipid profiles generated by the screen of 600 human 
kinases. Clustering was performed with the program CUPID using Pearson correlation and 
generated 10 phenotypic clusters. Phenotypes were described as increase (green) or 
decrease (red) in specific lipids or lipid ratios. Annotation was performed using CUPID and 
corrected manually when needed. 
PRKCE  protein kinase C, epsilon  
TRIO  triple functional domain (PTPRF interacting)  
CSS3R colony stimulating factor 1 receptor precursor
PRKWNK1  protein kinase, lysine deficient 1  
CHUK  conserved helix-loop-helix ubiquitous kinase  
ATR  ataxia telangiectasia and Rad3 related protein kinase  
TRIM33  tripartite motif-containing 33 protein  
PDK1  pyruvate dehydrogenase kinase, isozyme 1  
ERBB2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2  
TEK  TEK tyrosine kinase, endothelial  
TESK1  testis-specific protein kinase 1  
CSF1R  colony stimulating factor 1 receptor precursor
CAMK1G  calcium/calmodulin-dependent protein kinase IG  
MAPK12  mitogen-activated protein kinase 12  
CRK7  CDC2-related protein kinase 7  
PRKD2  protein kinase D2
CDKL3  cyclin-dependent kinase-like 3  
DYRK4  dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4  
CDK4  cyclin-dependent kinase 4  
CHEK1  CHK1 checkpoint homolog  
FER  protein tyrosine kinase fer  
ILK  integrin-linked kinase  
CDK2  cyclin-dependent kinase 2 isoform 2  
GK  glycerol kinase isoform a  
BMP2K (BIKE)  BMP-2 inducible kinase isoform a  
IRAK1  interleukin-1 receptor-associated kinase 1  
SPHK1  sphingosine kinase 1  
RIPK4 (ANKRD3) ankyrin repeat domain 3
PRKCI  protein kinase C, iota  
MKNK1  MAP kinase interacting serine/threonine kinase 1  
MAPK4  mitogen-activated protein kinase 4  
FLJ10074  similar to mouse D10Ertd802e protein  
PRKWNK2 (SDCCAG43)  lysine-deficient protein kinase 2  
EPHA5  ephrin receptor EphA5 isoform a 
TYK2  tyrosine kinase 2  
MAP3K7  mitogen-activated protein kinase kinase kinase 7 isoform D  
ADK  adenosine kinase isoform b  
NEK3  NIMA-related kinase 3  
MAP4K3  mitogen-activated protein kinase kinase kinase kinase 3  
BCKDK  branched chain alpha-ketoacid dehydrogenase kinase  
MUSK  muscle, skeletal, receptor tyrosine kinase
STK38  serine/threonine kinase 38  
MAPK9  mitogen-activated protein kinase 9 isoform 4  
LCK  lymphocyte-specific protein tyrosine kinase  
PANK1  pantothenate kinase 1 isoform beta  
PDXK  pyridoxal kinase 
CDK5R1  cyclin-dependent kinase 5, regulatory subunit 1  
RIPK3  receptor-interacting serine-threonine kinase 3  
CDC42BPA (PK428)  CDC42-binding protein kinase alpha isoform A
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Figure 25: Clustering of the phenotypic lipid profiles (continued). 
 
Among the phenotypes observed, several siRNAs induced a decrease in cholesterol 
and apparition of an additional lipid band running slightly further than cholesterol 
(figure 24, lane a). This band could be due to the accumulation of an intermediate of 
cholesterol biosynthesis. The running behavior of several sterols was then tested 
(figure 26). Among the sterols tested, the methylated sterols lanosterol and lophenol 
showed a similar running behavior as the new lipid band. On the basis of the 
biosynthetic pathway of cholesterol, this new band is likely to be due to the 
accumulation of the tri- or dimethylated precursors of cholesterol biosynthesis, 
lanosterol or demethyllanosterol respectively. Unfortunately, the accumulation 
seems to be only transient and, therefore the low abundance of this intermediate 
didn’t allow its direct identification by mass spectrometry. 
PKN1 (PRKCL1)  protein kinase N1 isoform 1  
ROCK2  Rho-associated, coiled-coil containing protein kinase 2  
CASK  calcium/calmodulin-dependent serine protein kinase (MAGUK family)  
PHKG2  phosphorylase kinase, gamma 2 (testis)  
PSKH2  protein serine kinase H2  
STK33  serine/threonine kinase 33  
CDK10  cyclin-dependent kinase 10 isoform 3  
CKMT1  ubiquitous mitochondrial creatine kinase precursor  
CSNK1A1L (MGC33182)  casein kinase 1, alpha 1-like  
MAP3K4  mitogen-activated protein kinase kinase kinase 4 isoform a  
ALPK1 (LAK)  alpha-kinase 1  
ALS2CR2  amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2  
EPHA3  ephrin receptor EphA3 isoform a precursor  
PGK2  phosphoglycerate kinase 2  
EPHB3  ephrin receptor EphB3 precursor  
ACVR1B  activin A type IB receptor isoform c precursor  
FLT1  fms-related tyrosine kinase 1 (vascular endothelial growth factor receptor)  
RYK  RYK receptor-like tyrosine kinase isoform 1
STK32C (MGC23665)  serine/threonine kinase 32C  
AKT2  similar to RAC-beta serine/threonine-protein kinase (RAC-PK-beta) (PKB beta)  
STK17A  serine/threonine kinase 17a (apoptosis-inducing) 
LOC51701 Nemo-like kinase
ITPKA  1D-myo-inositol-trisphosphate 3-kinase A  
CSNK1D  casein kinase 1, delta isoform 2  
MAP3K8  mitogen-activated protein kinase kinase kinase 8 
STK25  serine/threonine kinase 25  
FGFR3  fibroblast growth factor receptor 3 isoform 2 precursor  
ACVR1C (ALK7)  activin A receptor, type IC
NME7  nucleoside-diphosphate kinase 7 isoform b  
CKMT2  sarcomeric mitochondrial creatine kinase precursor  
PAPSS1  3'-phosphoadenosine 5'-phosphosulfate synthase 1  
ERN1  endoplasmic reticulum to nucleus signalling 1 isoform 1  
PIK3R4  phosphoinositide-3-kinase, regulatory subunit 4, p150  
CSNK1G2  casein kinase 1, gamma 2  
PAK3  p21-activated kinase 3  
EPHB4  ephrin receptor EphB4 precursor  
MAP3K14  mitogen-activated protein kinase kinase kinase 14  
IGF1R  insulin-like growth factor 1 receptor precursor  
MAP3K10  mitogen-activated protein kinase kinase kinase 10  
MAP3K11  mitogen-activated protein kinase kinase kinase 11  
RBKS  ribokinase  
UCK2 (UMPK)  uridine-cytidine kinase 2
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Figure 26: Running behaviour of cholesterol derivatives. 
The lanes 3 and 7 have been loaded with Hela lipid extracts while the other lanes were 
loaded with standards for the following sterol derivatives: lanosterol (lane 1), 7-
dehydrocholesterol (lane 2), lathosterol (lane 4), desmosterol (lane 5), lophenol (lane 6), 
epoxycholesterol (lane 8) and squalene (lane 9). Lipids were visualized upon charring with 
H2SO4. 
 
 
Validation of the screen 
 
Cholesterol is a major structural component of membranes and microdomains and 
has been implicated in several cellular processes. In addition, it is an important lipid 
in clinical studies because of its implication in several diseases like atherosclerosis 
and obesity. Therefore, the knock-downs that induce accumulation of a potential 
methylated cholesterol precursor, such as lanosterol, were further analyzed. Six 
kinases were selected because their depletion resulted in the strongest phenotypes. 
A new set of three siRNAs of different sequences was used to validate these results. 
However, although the phenotype could be reproduced using the pool of sequences 
1 3 2 4 5 6 7 8 9 
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used during the screen, there was no new lipid accumulating after treatment with a 
pool of three new sequences (figure 27). This strongly suggested that the phenotype 
observed during the screen was sequence-dependent. To check if the difference in 
phenotypes could result from variation of silencing efficiency between the 
sequences, mRNA level of the corresponding gene was measured by Real-Time 
PCR after siRNA treatment (figure 28). However, for most of the genes tested, the 
new set of sequences was inducing a stronger decrease in mRNA level than the 
sequences used during the screen. Therefore, the loss of phenotype observed could 
not result from a decreased silencing efficiency. The phenotype and mRNA level 
were also analyzed after treatment with individual siRNA sequences. Results from 
this more detailed analysis are summarized in table 4. As an example, the lipid 
phenotypes obtained using siRNAs targeting IKK1 are shown in figure 29. Out of the 
six sequences tested, only two induced the accumulation of the new lipid band, 
confirming the sequence dependency of the phenotype. 
 
 
Figure 27: Lipid phenotype upon siRNA treatment. 
Close-up of the cholesterol/lanosterol region of the TLC plate. Lipid extracts from Hela cells 
treated with pools of three siRNAs from the screen (red arrows) or pools of three siRNAs of 
new sequences (blue arrows) were separated on TLC plates and compared to controls in the 
following order: mock transfection, SOAT1, eg5 and no transfection. 14C-labeled lipids were 
visualized upon exposure on phosphorimager plate. 
 
IKK1 is a signaling kinase responsible for phosphorylation of the NFκB inhibitor iκB 
(Hayden & Ghosh 2004). Upon phosphorylation, iκB is degraded by the proteasome, 
releasing and thereby activating NFκB (Baldwin 1996, Hayden & Ghosh 2004). This 
protein was chosen to further analyze the sequence dependency of the lipid 
phenotype. The silencing efficiency of six siRNAs targeting this kinase was 
monitored both at the mRNA level by Real-Time PCR and at the protein level by 
western blotting (figure 30 a. and b.). At the mRNA level, the best knock-down was 
observed for the individual sequence 2, although this sequence didn’t induce any 
lipid phenotype. By western blotting, no protein was detectable after treatment with 
any of the siRNAs against IKK1, suggesting a strong silencing potency of all the 
sequences against this protein, even if the silencing at the mRNA level was not 
complete. This suggests that a silencing mechanism other than mRNA cleavage 
may also take place. Furthermore, this rules out the possibility that the difference in 
lipid phenotype observed could be due to a variation in protein silencing. In 
addition, the effect of siRNAs targeting NFκB1 and NFκB2 was monitored, but no 
CSF1R  TRIO IKK1  ATR RIPK4 WNK1 
controls controls 
 65 
lipid phenotype was observed in both cases (results not shown). Finally, Hela cells 
were treated with parthenolide, a known inhibitor of IKK (Kwok et al 2001). Upon 
increasing concentration, parthenolide induces cell death, but no accumulation of a 
new lipid band or decrease in cholesterol is observed (figure 30 c.). 
 
Figure 28: mRNA level upon siRNA treatment. 
RNA was extracted from Hela cells treated with pools of three siRNAs from the screen (red) 
or pools of three siRNAs of new sequences (blue) targeting the genes mentioned below the 
graph. mRNA level of the targeted genes were measured by Real-Time PCR and normalized 
to GAPDH mRNA. Level of the corresponding mRNA for mock transfected samples was set 
to 100%. 
 
This led to the conclusion that the lipid phenotype observed is not due to decrease 
in the targeted genes, but probably to the decrease of another, yet unidentified 
gene, a phenomenon known as off-target effect (Jackson et al 2003). 
 
Analysis of a wider set of genes was then carried out. This set included two kinases 
whose knock-down induces a strong decrease in one SM band, and 12 kinases 
whose knock-down induces an increase in TAG. Results of this analysis can be 
found in table 4. As for the previous kinases, most of the time, only one or two 
siRNA sequences were responsible for the lipid phenotype observed, and, when 
tested, no correlation could be found between the phenotype observed and the 
decrease in mRNA level. Only three kinases show a phenotype using three 
independent siRNAs: CASK, PDXK and MAPK9, the strongest phenotype being 
observed for the latest. 
 
SOAT1 IKK1 ATR TRIO RIPK4 
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Figure 29: TLC of Hela cells extracts upon IKK1 knock-down. 
Lipid extracts from Hela cells treated with a pool of three siRNAs against IKK1 from the 
screen (lane 1) or the corresponding individual sequences (lane 2-4) or with a pool of three 
siRNAs of new sequences (lane 7) or the corresponding individual sequences (lane 8-10) 
were compared to the S2 treated-cells (lane 5) and mock transfected control (lane 6). 14C-
labeled lipids were visualized upon exposure on a phosphorimager plate. The position of the 
phenotypic band is indicated by the arrow. 
 
 
1 2 3 4 5 6 7 8 9 10 
 67 
 
Figure 30: Effect of knock-down or inhibition of IKK1. 
(a) IKK1 mRNA levels and (b) protein levels were measured from Hela cells treated with a 
pool of three siRNAs from the screen (Op) or the corresponding individual sequences (O1, 
O2 and O3) or with a pool of three siRNAs of new sequences (Np) or the corresponding 
individual sequences (N1, N2 and N3). mRNA levels were measured by Real-Time PCR and 
normalized to GAPDH mRNA. Level of the corresponding mRNA for mock-transfected 
samples was set to 100%. (b) Protein levels were analyzed by western blotting and 
compared to the mock-transfected control and S2 treated-cells. Red arrows indicate the 
samples that give a lipid phenotype (c) Lipid extracts from Hela cells treated with increasing 
amount of parthenolide were separated by TLC. 14C-labeled lipids were visualized upon 
exposure on a phosphorimager plate. 
 
However the phenotype could not be reproduced using siRNAs from other 
companies neither for CASK nor for PDXK. Furthermore, the addition of pyridoxal 
phosphate, the enzymatic product of PDXK, didn’t rescue the phenotype (data not 
shown). On the contrary, the phenotype could be reproduced for MAPK9 with an 
additional siRNA from another company. 
 
All these data taken together, MAPK9 was selected to study its potential implication 
in triglyceride homeostasis. 
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Table 4: Lipid phenotype and RT-PCR data obtained for kinase knock-down. 
 
Screen sequences New sequences Invitrogen Qiagen
siRNA1 siRNA2 siRNA3 siRNA1 siRNA2 siRNA3
Cholesterol
CSF1R x o x o o o
IKK1 x o x o o o
16 8 12 19 21 24
ATR o x - - - -
15
RIPK4 x o x o o o
24 27 28 67 33 31
TRIO o o o o - -
PRKWNK1 x o o - - -
8
SM
CKMT2 o x o - - -
CSN1KG2 x o o - - -
TAG
PRKCL1 o o x - - -
ROCK2 x o x o o o o o
20 54 26 11 22 10
CASK x o x o x o o o
7 4 18
PHKG2 x o o o o o
MAPK9 o x x o x + CE o x
27 23 22 23 20 24
24
LCK dead x x dead dead dead o
PDXK x o x o x o o o
0.1 1 1
LAK o TAG CE - - -
MAP3K4 x x o o o o
51 33 30 3 15 34
ALS2CR2 o o x - - -
EPHB3 o o o - - -
FLT1 o o x - - -
x
o
-
10
10
32 15
15
5
20 31
23 6
% mRNA left (pooled siRNA)
phenotype
no phenotype
no siRNA
% mRNA left (individual siRNA)
29 17
9
19
14 16
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MAPK9: A potential regulator of triglyceride metabolism 
 
MAPK9, also known as the c-jun N-terminal kinase 2 (JNK2) (Kallunki et al 1994), is 
a member of the mitogen-activated protein kinase (MAPK) family (Karin & Gallagher 
2005, Manning & Davis 2003). There are three members in the JNK subfamily, 
termed JNK1, JNK2 and JNK3 (Bogoyevitch 2006). While JNK1 and JNK2 are 
ubiquitously expressed, JNK3 expression is restricted to the brain and testis. JNK 
proteins are activated through a typical MAPK cascade, through phosphorylation by 
the MAPK kinases MKK4 and MKK7 (Karin & Gallagher 2005, Manning & Davis 
2003). There is a wide range of upstream mediators, allowing JNK activation upon 
diverse stimuli. In turn, JNK phosphorylates several transcription factors, such as c-
jun or the activating transcription factor ATF2, as well as non-nuclear substrates, 
such as the B-cell leukemia associated oncogenes (Bcl) mitochondrial proteins 
(Bogoyevitch 2006). JNK proteins are strongly implicated in induction of apoptosis 
through the phosphorylation of the Bcl proteins that activate the apoptosis program 
(Putcha et al 2003, Yu et al 2004). Accordingly, the JNK1-/- JNK2-/- double knock-
out mice (Kuan et al 1999, Sabapathy et al 1999) dies in utero because of 
dysregulation of apoptosis in several parts of the brain, leading to defective neural 
tube closure. The individual knock-outs however are viable and develop normally. 
Nevertheless, impaired late differentiation of T lymphocytes is observed in these 
mice, delineating a role for JNK in the immune response (Dong et al 2000, Karin & 
Gallagher 2005). In addition, JNK proteins have been shown to get activated upon 
various environmental stresses, such as UV light (Derijard et al 1994), osmotic stress 
(Bogoyevitch et al 1995) or glucose deprivation (Liu et al 1997). 
 
Although these proteins, in particular JNK1 and JNK2, are partially redundant, they 
also have isoform-specific roles (Bogoyevitch 2006). Among these, of particular 
interest is the role of JNK2 in atherosclerosis (Sumara et al 2005). JNK2 is 
specifically activated in the aorta of high-cholesterol fed ApoE-/- mice, animal 
models for atherosclerosis (Ricci et al 2004). Similarly, JNK activation has been 
observed in human atherosclerotic lesions (Nishio et al 2001).  Furthermore, the 
double knock-out mice ApoE-/- JNK2-/-, but not ApoE-/- JNK1-/-, show decreased 
atherosclerotic lesions, compared to the ApoE-/- mice.  This is apparently due to a 
decreased phosphorylation of scavenger receptor A in macrophages of these 
double knock-out mice (Ricci et al 2004), resulting in impaired internalization of 
modified LDL, and thereby decrease in foam cells accumulation (Fong & Le 1999, 
Kosswig et al 2003). 
 
On the other hand, JNK1 has been linked to obesity since the JNK1-/- mice are 
partially resistant to high fat diet induced obesity and have an increased tolerance to 
high glucose or insulin level (Hirosumi et al 2002). Therefore, JNK1 is believed to be 
implicated in the development of insulin resistance and type II diabetes, via serine 
phosphorylation of the downstream effector of the insulin receptor, IRS1, leading to 
inhibition of the insulin response pathway (Aguirre et al 2000, Aguirre et al 2002). 
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Phenotypic characterization 
 
As mentioned in the previous chapter, four siRNAs targeting MAPK9 induce the 
same phenotype and MAPK9 appears therefore as a potential regulator of lipid 
metabolism. Knock-down of the kinase was confirmed both by Real-Time PCR 
(table 4) and by western blot (figure 32). Although four siRNAs show a consistent 
increase in TAG, one of the siRNAs shows in addition an increase in the level of 
another storage lipid: cholesterol ester (figure 31). To date, no evidence allows the 
distinction between an off-target effect of this sequence or a physiological relevance 
for the concomitant increase of these two classes of storage lipids. Although the 
initial data were obtained in delipidated medium, the increase of TAG could be 
confirmed in a medium that was not lipid-depleted. The phenotype was also 
observed upon oleate feeding and radioactive oleate staining of the cells (figure 33). 
 
Figure 31: Increase of TAG upon MAPK9 knock-down. 
The figure shows a close-up of the storage lipid region from the lipid profiles obtained after 
TLC. Intensities were normalized to the level of PC. The black profile represents the mock-
transfected negative control, the blue profiles the effect of siRNA O1, N1 and N3 targeting 
MAPK9, showing no phenotype, and the red profiles the effects of siRNA O2, O3 and N2 
targeting MAPK9, showing an increase in TAG level. The siRNA N2 shows in addition an 
increase in the signal corresponding to the upper band, cholesterol ester, visible here by the 
shoulder in the lipid peak. 
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Figure 32: Knock-down of MAPK9 monitored by western blot. 
Hela cells were treated using a pool of 3 siRNAs targeting MAPK9 (Op and Np) or the 
corresponding individual sequences (O1, O2, O3, N1, N2 and N3) and the level of MAPK9 
protein (55kDa) was compared for the different knock-downs and the mock transfection 
control (M). The unspecific band located around 35 kDa can be considered as a loading 
control. 
 
 
 
 
 
 
Figure 33: Radioactive labeling of TAG upon MAPK9 knock-down. 
Hela cells were fed with oleate and radioactive oleate 4h after siRNA transfection. Lipids 
were extracted 48h after transfection and separated by TLC. Radioactive signal was 
revealed by autoradiography. siRNA used for transfection are indicated on the figure. A pool 
of the three sequences from the screen was used for MAPK9. 
 
The effect of SP600125, a specific JNK inhibitor (Bennett et al 2001) was also 
tested. Although this inhibitor induces some cell death at higher concentration, the 
ratio between TAG and the other lipids is increasing upon SP600125 treatment, 
further suggesting that this effect is specific for the down-regulation of MAPK9 
(figure 34). Nevertheless, it should be noted that a concomitant decrease in 
cholesterol is observed upon inhibitor treatment. This effect could be due however 
to the inhibition of other kinases, considering the poor specificity of the compound 
(Bain et al 2003). 
 
The phenotype was then confirmed using mass spectrometry. Lipid extracts from 
Hela cells treated with a pool of siRNAs targeting MAPK9 were analyzed by MS by 
Dominik Schwudke. There again, an increase in TAG was observed. Since MS 
analyzes the lipid composition of the cells as a whole, these data demonstrate that 
the phenotype reflects the status of the full TAG pool and not only an increase in 
newly synthesized TAG. Furthermore, mass spectrometry allows analysis of 
individual lipid species. The effect of MAPK9 knock-down on the level of individual 
TAG species was then analysed. As shown in figure 35, an increase was observed in 
all the TAG species monitored, suggesting no species specificity in the phenotype.  
 
 
Op O1  O2 O3 Np N1  N2 N3 M Eg5 
34 kDa 
85 kDa 
49 kDa 
MAPK9 Mock S6 Eg5 
TAG 
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Figure 34: Effect of SP600125 on lipid composition. 
Hela cells were treated with various concentration of SP600125 as indicated on the figure. 
The lipid extracts from these cells were then separated by TLC. 14C-labeled lipids were 
visulalized upon exposure on phosphorimager plate. 
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Figure 35: Effect of MAPK9 knock-down on individual TAG species monitored by LTQ-
Orbitrap mass spectrometry. Values have been normalized on the level of the lipid species 
PC 34:1. 
 
Inside the cell, TAG is found mainly in specialized organelles called lipid droplets. 
These organelles can be specifically labeled using BODIPY (Gocze & Freeman 
1994). Cells were therefore stained with BODIPY upon MAPK9 knock-down. In 
delipidated conditions, almost no lipid droplets are detectable in wild-type cells. 
However, upon knock-down of MAPK9, BODIPY stains small round structures 
characteristic of lipid droplet staining (figure 36). When a high quantity of oleate is 
provided to the cells in order to favor lipid droplets accumulation, a small increase in 
BODIPY staining is still visible in the MAPK9 knock-down, although much less 
significant that in the absence of extracellular lipids (figure 36). 
 
Taken together, these data strongly suggest a role of MAPK9 in the regulation of 
TAG homeostasis. As a MAP kinase, MAPK9 can act by direct phosphorylation of its 
cytoplasmic target, directly affecting the activity of the protein, or, most commonly, 
by activation of transcription factors that activate, or eventually inhibit, the 
expression of other genes. Therefore, the expression of genes of the TAG 
biosynthetic or degradation pathways was monitored to check if they were affected 
in the MAPK9 knock-down. 
 
TAG can be synthesized via different pathways (Coleman & Lee 2004). The major 
one originates from glycerol-3-phosphate, which is combined with a fatty acid by 
the glycerol-phosphate acyltransferase (GPAT) to form lysophosphatidic acid (LPA). 
LPA is first acylated by the acylglycerol-phosphate acyltransferase (AGPAT) to form 
PA. Then PA is dephosphorylated by lipin1 to form DAG, which in turn is acylated by 
diacylglycerol acyltransferase (DGAT) proteins to yield TAG (Coleman & Lee 2004). 
To test the effect of the MAPK9 knock-down on TAG biosynthesis, the expression of 
the enzymes AGPAT and lipin1 was monitored by RT-PCR, but no increase in the 
expression of these genes was observed. On the contrary, a small decrease in 
expression was observed for lipin1, which could be a compensatory effect due to 
the increase in TAG. Then, the expression of the hormone-sensitive lipase (HSL) and 
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the adipose triglyceride lipase (ATGL) was also monitored both by RT-PCR and WB. 
These two lipases are known to hydrolyze the TAG from lipid droplets (Haemmerle 
et al 2006, Holm et al 2000, Zimmermann et al 2004). However, no variation in 
expression of these genes was observed, neither using RT-PCR, nor WB (figure 37). 
Similarly, no change in ATGL expression was observed upon UV (Derijard et al 1994) 
or anisomycin  (Iordanov et al 1997) activation of JNK (figure 38). 
 
 
Figure 36: Effect of MAPK9 knock-down on BODIPY staining. 
Untransfected A431, mock-transfected A431 and A431 cells transfected with scramble or 
MAPK9 siRNA were transferred to a medium containing delipidated serum or a medium 
supplemented with oleate 24h before fixation. Lipid droplets were stained using the lipid dye 
Bodipy493/503. Images were taken by Julia Massier. 
 
 
 
 
 
 
 
Figure 37: ATGL and HSL levels monitored by WB upon MAPK9 knock-down. 
Hela cells were transfected with the siRNA indicated at the top of the picture (a pool of the 
three sequences from the screen was used for MAPK9). Cells were harvested 72h after 
transfection and analyzed by western blot using ATGL and HSL primary antibodies. 
ATGL 
HSL 
mock S6 MAPK9 
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Figure 38: ATGL levels monitored by WB upon JNK activation. 
The level of ATGL was monitored by western blot upon JNK activation by 2h anisomycin 
(AM) treatment or 10’ UV excitation (200W). Activation of JNK was verified using a phospho-
specific JNK antibody. 
 
However, other genes implicated in these processes may be the targets of MAPK9 
signaling. Moreover, variation in their activity may be regulated at the post-
transcriptional rather than at the transcriptional level. Therefore, more general assay 
may be necessary to evaluate MAPK9 influence on TAG metabolism. 
 
 
Sty1: A potential homolog of MAPK9 in S. pombe 
 
To further confirm the specificity of the phenotype and the role of MAPK9 in the 
regulation of TAG metabolism, a MAPK9 homolog in yeast was also analyzed. Gene 
deletion in yeast is a much better established technique and it is therefore possible 
to study the effect of gene knock-out in that organism, a system much less prone to 
off-target effects. 
 
The JNK and p38 subfamilies of MAP kinases are often referred to as the stress-
activated kinases, because of their role in response to several external stress stimuli 
(Bogoyevitch 2006, Tibbles & Woodgett 1999). In yeast, both S. cerevisiae and S. 
pombe contain one stress-activated kinase, named High osmolarity glycerol kinase 
1 (Hog1) and Suppressor of tyrosine phosphatase 1 (Sty1) respectively (O'Rourke et 
al 2002, Toone & Jones 1998). While Hog1 is activated upon osmotic stress only 
(O'Rourke et al 2002), Sty1 is activated upon a wide-range of stimuli, like the 
mammalian kinases (Chen et al 2003, Degols et al 1996). Furthermore, Sty1 is 
activated upon glucose deprivation such as MAPK9 (Stettler et al 1996) and appear 
therefore as a potential homolog of that kinase in yeast. 
 
To test this hypothesis, the accumulation of lipid droplets in the Sty1 deletion strain 
JM1160 was visualized. For this purpose, cells were labeled with the hydrophobic 
dye Nile Red (Greenspan et al 1985, Tong et al 2006). As shown in figure 39 (upper 
panels), there is a strong increase in lipid droplet staining by Nile Red in the Sty1 
deletion strain compared to the wild-type strain PR109, confirming the homology 
between the mammalian and the yeast protein. Consistent with this observation, an 
increase in TAG upon labeling with radioactive oleate was visible in the Sty1 deletion 
mutant (figure 40, lane 1 and 3). 
- AM - UV 
MAPK9 (JNK2) 
MAPK8 (JNK1) 
ATGL 
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The same yeast strains were then analyzed upon glucose depletion. In this case, the 
glucose present in the medium was replaced by sorbitol to maintain the osmolarity 
of the growth medium (Madrid et al 2004). Sorbitol however can’t be used as a 
carbon source by S. pombe. In these conditions, yeast arrest in G2 phase till 
glucose is added again to the medium. Interestingly, Nile Red staining of wild-type 
cells shifts from the lipid droplet structures to a more diffuse staining of the nuclear 
membrane and some other undefined structure in the cytoplasm (figure 39 (lower 
panels)). Comparatively, in the Sty1 mutant strain, although some more diffuse 
staining is observed, there is still a prominent lipid droplet staining (figure 39 (lower 
panels)). One could hypothesize that this shift in labeling observed in wild-type yeast 
was due to the loss of lipid droplets resulting from the use of TAG as an alternative 
energy source. However, oleate labeling of these yeasts shows an increase in TAG 
level upon glucose depletion, both for the wild type and the mutant yeasts (figure 
40, lane 2 and 4). This implies that upon glucose depletion, TAG accumulates in 
another organelle rather than in lipid droplets and that this process is at least 
partially impaired in the Sty1 deletion strain. 
 
 
 
Figure 39: Nile Red staining with or without glucose depletion. 
The wild-type strain PR109 (left panels) and the Sty1 deletion strain JM1160 (right panels) 
have been stained with Nile Red after 1 hour growth in glucose-containing EMM2 (upper 
panels) or glucose-free EMM2 (lower panels). 
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Figure 40: Radioactive oleate staining of yeast lipid extracts separated by TLC. 
Lipid extracts from the wild type strain PR109 (lane 1,2) and the Sty1 deletion strain JM1160 
(lane 3,4) were separated on TLC plate and the radioactive signal was obtained by 
autoradiography. Yeast cells were either grown in glucose containing (G: lane 1 and 3) or in 
glucose-free EMM2 for 1h (S: lane 2 and 4).  
 
TAG differs in structure from the phospholipids and harbors a conical shape due to 
the third fatty acid. Therefore this lipid is not well suited for lipid bilayer structure. 
However, in vitro studies showed that a small amount, namely 3% of TAG can 
accumulate in artificial membranes (Hamilton 1989). Because of the nuclear 
membrane staining of Nile Red, the accumulation of TAG could occur in the 
endoplasmic reticulum (ER). To test this possibility, the PG2747 yeast strain was 
used. This strain encodes for a GFP-tagged truncated ER resident protein, the 
NADPH-P450 reductase (Ding et al 2000). A nice staining of the nuclear membrane 
and the cortical ER, which locates just below the plasma membrane, is observed in 
normal growth conditions (figure 41). However, upon glucose depletion, a similar 
WT ΔSty1 
TAG 
oleate 
G S G S 
PE, PI 
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staining is observed, which differs from the Nile red staining observed in these 
conditions. This suggests that the structure in which the dye accumulates is distinct 
from the ER. Furthermore, by bright-field microscopy, less internal structures are 
visible in the yeasts upon glucose depletion (figure 42). This difference can be 
partially explained by the decrease in lipid droplets under these conditions. 
However, since not all these internal structures co-localize with the Nile Red staining 
in wild-type cells, it suggests that some other internal structures are disturbed under 
glucose-free conditions, potentially the vacuoles. 
 
Figure 41: No effect of glucose depletion on ER structure. 
Yeast cells from the PG2747 strain, coding for the GFP-tagged truncated NADPH-P450 
reductase were grown for 1h in glucose containing (left panel) or in glucose-free EMM2 (right 
panel). 
 
Figure 42: Decrease in visible internal structure upon glucose depletion observed by bright-
field microscopy. Yeasts from the PG2747 strain were grown for 1h in glucose containing 
(left panel) or glucose-free EMM2 (right panel). 
 
In yeast, nutrient depletion induces growth arrest. In S. cerevisiae, it is known that 
upon glucose depletion, cells accumulate glycogen and triglycerides (Francois & 
Parrou 2001, Werner-Washburne et al 1993). These are then used upon stress 
release to leave the arrested state. The accumulation of TAG could have a similar 
purpose in S. pombe. Therefore, the growth recovery of both the mutant strain and 
With glucose Without glucose 
With glucose Without glucose 
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the wild-type strain were monitored after a growth arrest due to nutrient stress. Cells 
were maintained for 20h under glucose-free conditions. Then, the medium was 
replaced for a classical EMM2 medium containing glucose. The Sty1 deletion strain 
JM1160 shows a slight impairment in growth compared to the wild-type strains 
PR109 and L972 (figure 43). However, a similar growth impairment is observed 
when the cells are always maintained in glucose-containing medium. This suggests 
that either the recovery after glucose depletion is not impaired in the Sty1 deletion 
strain, or that the glucose present in the recovery medium is sufficient to provide the 
energy necessary for the recovery. 
 
 
Figure 43: Growth curve upon recovery from glucose depletion. 
The growth of the Sty1 deletion strain JM1160 was compared with the growth of the wild-
type strains PR109 (WT1) and L972 (WT2) in supplemented EMM2 (left) or in supplemented 
EMM2 after 20h growth arrest in glucose-free conditions (right). Optical Density (OD) was 
measured at 600 nm. When OD was above 1, yeast cultures were diluted 5x and the 
measured OD was then multiplied 5x to ensure linearity of the measurement. 
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Discussion 
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Dysregulation of lipid metabolism is a major cause of some of the most common 
diseases in our societies. Understanding its molecular basis and identifying the 
players of this process are therefore major challenges for the identification of new 
potential drug targets. In the context of this thesis, a screening procedure was 
developed, which allows to delineate the implication of some genes in the 
maintenance of lipid homeostasis. This method is based on a combination of RNA 
interference and lipid analysis by TLC and has proved to be successful for 
observing alterations of lipid composition upon specific siRNA treatment. Using TLC 
as a read-out system, modifications can be observed in all lipid classes. However, 
most phenotypes were affecting cholesterol, cholesterol esters and triglycerides. 
These lipids, being more subject to variation in the human body upon changes in 
diet or health status, may be similarly more subject to variation in cells, while the 
pool of glycerophospholipids, which have a more structural role, is more constant.   
 
In parallel, the potency of mass spectrometry as a lipid analysis tool in the context 
of large-scale studies was investigated. MS extends the analysis to individual lipid 
species and not only classes, thereby giving rise to a more complete overview of the 
lipid status of a cell. In particular, changes in saturation of the fatty acyl chains of 
glycerophospholipids and sphingolipids, which is a major factor for membrane 
fluidity or membrane microdomains (Simons97), can be assessed by MS and not by 
TLC. In addition, its high sensitivity allows analysis of lipid extracts without any need 
for labeling. Thereby, the analysis is not limited to the study of newly synthesized 
lipids but really gives an overview of the lipid status of the cell as a whole. MS 
appears therefore as a powerful tool to study lipid composition. 
 
For sample injection, the robotic nanoflow ion source Nanomate, which allows 
automatic injection of samples from a 96 well-plate, increases the potential of MS 
for larger-scale analysis (Schultz et al 2000). However, a major drawback of the use 
of MS for lipid analysis is the fact that it requires lipid extracts of high quality. One 
phase lipid extracts such as the ones used for TLC analysis contain too many 
contaminating molecules that impair injection of the samples and induce significant 
background, limiting the detection of less abundant lipid species. However, several 
methods could overcome this problem. First, labeling of the lipids using radioactive 
precursors or precursors containing non radioactive isotopes, such as deuterium or 
13C, could allow better identification of the lipids relative to the background. 
However, while the radioactive isotopes will radioactively contaminate the mass 
spectrometers, the non-radioactive isotopic precursors are most of the time not 
commercially available. Furthermore, the presence of non-labeled contaminants in 
the sample can still impair the sample injection and induce suppression of the ions 
of interest. Another alternative is the use of automated two-phases extraction. 
Schwudke et al. are currently developing a two-phases system based on methyl-
tert-butylether. In this system, the organic phase has a lower density, and is then 
above the aqueous phase and more accessible for direct injection by the Nanomate. 
This would generate easily accessible high quality lipid extracts suitable for large-
scale analysis (personal communication). Moreover, Schwudke et al. developed with 
our collaboration a method, based on PCA, which allows easy identification of lipid 
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modifications despite the large amount of data produced by MS analysis (Schwudke 
et al 2007). It therefore appears that only minor improvements are still necessary to 
use MS as a lipid analysis tool for large-scale analysis. 
 
 
Off-target Effects 
 
Although several siRNA knock-downs gave rise to modifications in lipid 
composition, most of these phenotypes appeared to be due to potential off-target 
effects. When it was initially discovered, RNA interference was considered as a 
revolutionary tool, both because of its ease and of its specificity. It was suggested 
that only genes that show a perfect complementation to a siRNA would be targeted, 
and mismatches of just one nucleotide would be sufficient to disrupt this effect 
(Elbashir et al 2001a). However, more recently, several reports suggested that this 
rule is not always applying and that expression of several unintended genes is also 
affected by the use of a given siRNA (Birmingham et al 2006, Jackson et al 2003, Lin 
et al 2005, Ma et al 2006). One possibility could be that siRNA molecules can be 
processed in the cells like the endogenous miRNAs. The human genome, as well as 
the genome of other organisms, encodes small genes generating RNA stem loop 
structures (Bartel 2004, Kim & Nam 2006). These molecules are then successively 
processed by Drosha and Dicer, two RNaseIII-like enzymes generating an imperfect 
siRNA-like duplex (Lee et al 2003b). Conversely to siRNAs that induce cleavage of 
their mRNA targets (Elbashir et al 2001b, Hammond et al 2000), miRNAs are mainly 
responsible for translational repression (Bartel 2004, Kim & Nam 2006). Only partial 
complementarity is sufficient, which results in down-regulation of multiple genes by 
a single miRNA. The off-target effects observed upon siRNA treatment could 
therefore arise from partial complementarity to untargeted genes and subsequent 
inhibition of translation (Doench et al 2003, Saxena et al 2003, Scacheri et al 2004, 
Zeng et al 2003). However, since some miRNAs have also been shown to regulate 
their targets at the mRNA level (Lim et al 2005), similar unintended mRNA down-
regulation could also occur upon siRNA treatment (Jackson et al 2003, Lin et al 
2005). 
 
Among the screens that have been previously carried out, although some of them 
didn’t seem to suffer from off-target effects (Kittler et al 2004, MacKeigan et al 2005, 
Pelkmans et al 2005), others also concluded that their major phenotypes were 
actually due to the down-regulation of unintended genes (Lin et al 2005, Ma et al 
2006). In particular, Lin et al. showed that a partial complementation of only 7 
nucleotides was sufficient to induce mRNA down-regulation of an unintended gene 
(Lin et al 2005). These 7 nucleotides correspond to the seed region of miRNA, which 
is also necessary for miRNA-induced down-regulation (Birmingham et al 2006, 
Jackson et al 2006, Lin et al 2005). 
 
The difference in off-target occurrence between these various screens could arise 
from several causes. First, in the screens that don’t show off-targets, only a small 
subset of genes has been tested. It is therefore not unlikely that other phenotypes 
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are due to off-target effects. Furthermore, it is possible that some cellular processes 
would be more sensitive to off-target effects than others. In the case of lipid 
metabolism, several miRNAs have been implicated in its regulation (Esau et al 2006, 
Esau et al 2004, Krutzfeldt et al 2005, Krutzfeldt & Stoffel 2006, Teleman et al 2006, 
Xu et al 2003). It is possible that several genes implicated in lipid homeostasis are 
targets of miRNAs and would therefore be more sensitive to unintended down-
regulation by siRNA (Jackson et al 2006, Stark et al 2005). Supporting this 
hypothesis, a high proportion of genes implicated in lipid metabolism have long 3’ 
untranslated region (UTR), the part of the gene that is preferentially targeted by 
miRNAs. However, no homology has been found between the siRNAs from this 
screen believed to generate off-target effects and the already identified miRNAs. 
Nevertheless, some miRNAs still wait to be discovered and other sequences in the 
3’UTR could be responsible for the off-targeting. Unfortunately, considering the high 
number of genes that contain a 7nt complementarity to a given siRNA in their 
3’UTR, such homology can’t be used to identify the potential off-targets 
(Birmingham et al 2006). 
 
Another astonishing feature of the potential off-target effects observed in the screen 
is the fact that several targeted genes show the same potential off-target 
phenotypes upon treatment with two independent siRNAs although other siRNAs 
inducing a similar or stronger knock-down of the targeted gene do not induce any 
phenotype. Statistically, it seems very unlikely that several siRNAs would induce the 
same off-target effect. A potential explanation of that phenomenon could be that the 
down-regulation of both the target and an off-target would be responsible for the 
phenotype. In a system such as the regulation of lipid metabolism, redundancy is to 
be expected, and down-regulation of two independent pathways may be necessary 
for induction of a lipid phenotype. This hypothesis is however difficult to test without 
knowing the potential off-targeted genes. 
 
Several suggestions have been made to decrease the occurrence of off-target 
effects. One of them is the use of lower siRNA concentration. It has been suggested 
that decreasing the siRNA concentration would not impair down-regulation of the 
targeted gene, but decrease the occurrence of off-target effects (Persengiev et al 
2004). But, if this may be true for very efficient siRNAs, down-regulation of the target 
may be affected upon use of a less potent siRNA, thereby increasing the occurrence 
of false negatives in a screen. For this reason, high siRNA concentrations were also 
used in previous screens (MacKeigan et al 2005, Pelkmans et al 2005). Furthermore, 
decreasing the siRNA concentration most of the time didn’t disrupt the potential off-
target phenotypes (results not shown). Similar conclusions were also reached by 
others (Jackson et al 2003). Similarly, esiRNAs have been suggested to generate 
less off-target effects due to the low concentration of any individual sequence 
(Kittler et al 2007). However, although some esiRNAs were very potent in knocking-
down their targets, some others showed only minor down-regulation, thereby also 
increasing the occurrence of false negatives in a screen. However, these two 
methods are a sensible compromise to limit off-target effects. 
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Another possibility is to directly compare the effect of several individual sequences 
targeting the same gene in the primary screen. Although difference in efficiency may 
result in different phenotypes, it again appears as a sensible way to directly select 
potential real targets. In addition, nowadays, most suppliers have improved their 
siRNA design to reduce off-target effects. Yannis Kalaidzidis has developed a 
method that allows evaluation of the quality of a library. Following this multi-
parametric method, an old library against motor proteins (generated using the same 
algorithm as the kinase library used in this screen) led to approximately 75% non-
correlating phenotypes, while the last generation of kinase library from the same 
company only generates around 25% non-correlating phenotypes (personal 
communication). Further understanding of the RNA interference process and further 
improvement of the siRNA design accordingly may therefore be sufficient to 
generate meaningful screening results. 
 
 
Regulation of Cholesterol Metabolism 
 
Despite the prominent off-target problems encountered in the screen, some 
interesting observations could be made. The first one is the fact that several siRNAs 
induce a decrease in cholesterol and a simultaneous accumulation of a potential 
methylated sterol precursor. Interestingly, some of these siRNAs were also reported 
to inhibit endocytosis in a previous screen (Pelkmans et al 2005), suggesting an 
important role for cholesterol in this process. 
 
So far, regulation of HMG-CoA reductase was believed to be the major regulation 
step in the synthesis of cholesterol (Goldstein & Brown 1990). However, the 
accumulation of methylated sterols suggests that an additional important regulatory 
step exists downstream in the cholesterol biosynthetic pathway. In humans, two 
cholesterol precursors are methylated, namely lanosterol and demethyllanosterol. 
They appear therefore as potential regulatory species. Lanosterol has been shown 
to be instrumental in down-regulation of HMG-CoA reductase by promoting its 
Insig-dependent ubiquitination and degradation (Song et al 2005a). Furthermore, 
lanosterol proved to be toxic when added to CHO-7 cells in delipidated medium, 
although other natural sterols didn’t impair cell growth (Xu et al 2005). Viability could 
be recovered by addition of cholesterol suggesting a role of lanosterol in inhibiting 
cholesterol synthesis. In addition, the downstream enzyme, CYP51, which catalyzes 
the lanosterol demethylation to form demethyllanosterol, is the most evolutionarily 
conserved cytochrome P450 enzyme and the only one found both in prokaryotes 
and eukaryotes (Debeljak et al 2003, Waterman & Lepesheva 2005). As the other 
enzymes of the cholesterol biosynthetic pathway, it is activated upon SREBP 
activation (Rawson 2003). However, since additional sequences are highly 
conserved in the CYP51 promoter, other regulation systems are to be expected 
(Debeljak et al 2003). On the other hand, demethyllanosterol, also called follicular 
fluid meiosis-activating sterol (FF-MAS), has been identified as a signaling molecule 
responsible for the induction of meiosis in germ cells (Byskov et al 1995). 
Furthermore, the increase in FF-MAS in these cells is coupled to a decrease of free 
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cholesterol (Baltsen et al 2001). Therefore, accumulation of this molecule may also 
be tightly regulated in cells. 
 
Unfortunately, at this stage, the gene that is responsible for the methylated sterol 
accumulation is not yet identified and therefore these hypotheses can’t be 
confirmed. 
 
 
Regulation of Triglyceride Metabolism via MAPK9 
 
One of the phenotypes frequently observed within the screen was the increase of 
triglycerides. Triglycerides represent the most condensed form of energy in the cell 
and are therefore essential lipids for energy storage. They are found mostly in lipid 
droplets, specific organelles specialized in lipid storage. 
 
Although most of the siRNAs inducing TAG increase seem to do so via off-target 
effects, four siRNAs targeting MAPK9 showed a consistent phenotype without 
obvious off-target effects. This leads to the identification of MAPK9 as an essential 
regulator of lipid droplet metabolism. The increase in TAG could be confirmed both 
by TLC and by mass spectrometry. Furthermore, a similar phenotype was observed 
using an inhibitor of MAPK9. In addition, this effect was coupled to an increase in 
lipid droplets, as could be observed by BODIPY staining upon MAPK9 knock-down. 
 
To further confirm the specificity of the phenotype, the potential homolog of MAPK9 
in S. pombe, Sty1, was also analyzed. Although Sty1 is more closely related to the 
p38 subfamily of MAP kinases, both the JNK MAP kinases, from which MAPK9 
belongs, and Sty1 are activated upon glucose depletion (Liu et al 1997, Stettler et al 
1996). Furthermore, both are cytoplasmic proteins that translocate to the nucleus 
upon activation, while p38 kinases localization is not altered upon activation (Toone 
& Jones 1998). In addition, complementation studies with the S. cerevisiae homolog 
of Sty1, Hog1, showed that both JNK and p38 kinases could partially substitute for 
the loss of Hog1 (Galcheva-Gargova et al 1994, Han et al 1994). All these data taken 
together suggest that Sty1 could be a functional homolog of MAPK9. Accordingly, it 
is shown in this work that deletion of this gene induces both an increase in TAG and 
an increase in lipid droplets. 
 
Taken together, these data suggest that both MAPK9 and its S. pombe homolog 
Sty1 are implicated in the regulation of TAG metabolism and lipid droplets. 
 
Previously, MAPK9 has already been implicated in atherosclerosis, a major disease 
arising from dysregulation of lipid metabolism. Activation of MAPK9 was observed in 
atherosclerotic lesions both in mice and humans (Nishio et al 2001, Ricci et al 2004). 
Deletion of MAPK9 in atherosclerosis mouse model decreased the occurrence of 
the lesions (Ricci et al 2004). This appeared to be due to a decrease in LDL 
internalization by macrophages, following defective phosphorylation of scavenger 
receptor A, one of the main receptors for modified LDL, and concomitant decrease 
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in foam cell formation (Ricci et al 2004). This confirms the implication of MAPK9 in 
lipid-related processes. 
 
However, since in this assay the strongest phenotype was observed in delipidated 
conditions, MAPK9 must influence TAG metabolism directly at the intracellular level. 
Therefore, the phenotype observed could arise both from an increase in lipid 
synthesis or a decrease in lipolysis (figure 44). As it was previously shown, PPARγ is 
down-regulated by JNK activation (Camp et al 1999). Knock-down of MAPK9 would 
therefore release the inhibition of PPARγ. Since PPARγ is stimulating fatty acid 
uptake and synthesis (Beaven & Tontonoz 2006, Chawla et al 2001b), this could 
account for the increase in TAG observed in the MAPK9 knock-down. However, 
several lines of evidence would rather favor a decrease in lipolysis. In adipocytes, 
TNFα has been shown to induce lipolysis in a JNK-dependent fashion (Ryden et al 
2004). This happens via down-regulation of perilipin expression, a lipid droplet 
associated protein thought to modulate the access of the lipases to the lipid droplet 
surface (Souza et al 1998). Perilipin is not expressed in non-adipose tissues, but a 
similar mechanism could take place with a yet unidentified lipid droplet protein. 
Furthermore, JNK proteins are activated upon glucose depletion (Liu et al 1997). In 
these conditions, cells need to obtain their energy from other sources, such as TAG. 
MAPK9 could therefore be implicated in that process. Interestingly, upon activation 
of Sty1, several genes involved in peroxisomal β-oxidation are up-regulated (Chen et 
al 2003), further favoring the lipolysis hypothesis. To test this possibility, the level of 
mRNA of several genes implicated in biosynthesis or degradation of TAG was 
monitored upon MAPK9 knock-down and activation, but no significant variation 
could be observed. But, since other genes than the ones tested could be implicated 
and since regulation could occur at the post-transcriptional level, a more general 
assay will be required to delineate the mechanism of TAG regulation by MAPK9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Model of MAPK9 actions. 
MAPK9 would inhibit TAG synthesis and/or favor TAG mobilization. Upon MAPK9 
knock-down, these processes would be reversed inducing accumulation of TAG.
TAG 
G3P + AcylCoA 
FA + Glycerol 
MAPK9 
MAPK9 
TAG 
G3P + AcylCoA 
FA + Glycerol 
MAPK9 
MAPK9 
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Sty   Suppressor of tyrosine phosphatase 
TAG   Triacylglycerol 
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